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that we do not have vaccines against. To address this problem, universal influenza vaccines that target
the conserved HA stalk domain are currently being developed. In this dissertation we explore the
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ABSTRACT

PROTECTIVE POTENTIAL OF H1N1 INFLUENZA HEMAGGLUTININ STALK DOMAIN
ANTIBODIES: IMPLICATIONS FOR A UNIVERSAL INFLUENZA VACCINE
Shannon Renee Christensen
Scott E. Hensley

Influenza A viruses pose a significant threat to public health. Seasonal circulation of
influenza viruses causes significant morbidity and mortality each year, despite widespread seasonal vaccination. Influenza viruses continually acquire substitutions in the viral
membrane protein hemagglutinin (HA), the primary target of human immunity, thus
allowing viruses to escape vaccine-induced immunity through a process called antigenic
drift. Additionally, pandemic influenza strains occasionally enter the human population that
we do not have vaccines against. To address this problem, universal influenza vaccines
that target the conserved HA stalk domain are currently being developed. In this
dissertation we explore the protective capacity of antibodies that target the HA stalk
domain and the durability of this domain as a vaccine target. We used human serological
cohorts to demonstrate for the first time that HA stalk antibodies are associated with
protection against influenza infection and severe disease. In addition, we used a
humanized mouse model to demonstrate the in vivo protection of HA stalk antibodies
against severe influenza disease. We next determined that the HA stalk domain is
acquiring amino acid substitutions and assessed the antigenic effect of these substitutions
using a human serological cohort. We demonstrate that these substitutions do not reduce
binding of HA stalk antibodies in polyclonal human sera, suggesting this domain has not
experienced antigenic drift during the past decade of seasonal circulation. Overall, the
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work presented here identifies a potential correlate of protection that can be used for HA
stalk-based universal influenza vaccine trials and establishes the HA stalk domain as a
durable vaccine target.
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CHAPTER 1

INTRODUCTION

Section 1.1 - A global perspective
Just over 100 years ago, the greatest recorded pandemic in human history
ravaged the world: the 1918 ‘Spanish’ Influenza. This novel influenza virus made the leap
into human circulation from an animal reservoir, initiating three pandemic waves which
resulted in an estimated 50-100 million deaths worldwide – a greater loss of human life
than even the First World War [1, 2]. Since 1918, the viral descendants of this pandemic
influenza strain have continued to circulate in humans, undergoing reassortment with
other influenza strains and causing four additional pandemics over the past century.
Modern seasonal influenza strains still contain genes that can be traced back to the 1918
ancestral influenza strain [3].
Influenza epidemics occur each year, despite widespread vaccination efforts.
Seasonal influenza vaccine effectiveness is highly variable, ranging from 19-60% efficacy
over the past decade, with previous years seeing efficacy as low as 10% [4]. Additionally,
annual vaccination does not provide long-term protection, in part due to the ability of
influenza virus to evade host immune responses [5]. While it is difficult to estimate the
incidence of influenza infection worldwide due to limited surveillance in some regions, the
CDC estimates that during the 2017-2018 influenza season approximately 45 million
influenza infections occurred in the US alone, resulting in about 810,000 hospitalizations
and 61,000 deaths [6]. Additionally, the Burden of Communicable Diseases in Europe
project recently completed a study to assess the impact of infectious diseases on
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population health within the European Union; of the 31 infectious diseases examined
(including HIV and tuberculosis), influenza infection was ranked highest, generating about
30% of the total disease burden [7].
While the estimates of disease burden are alarming, of greater concern is the
possibility of a pandemic influenza strain entering the human population. The emergence
of a pandemic influenza strain would dramatically increase morbidity and mortality rates
around

the

world,

and

precipitate

unprecedented

economic

burden.

The

interconnectedness of individuals on the planet has been a large determinant in the spread
of influenza viruses and their subsequent epidemics and pandemics throughout history.
During the 1918 influenza pandemic, the high density population of military barracks
provided efficient transmission conditions for influenza viruses, while large-scale
movement of military troops continually carried the emerging pandemic strain to naïve
populations [8]. Accelerated international travel for business, commerce, and tourism has
been associated with the rapid spread of influenza viruses, including the 2009 H1N1
pandemic strain (pH1N1) [9]; indeed, a person can now fly to any major urban center in
the world within the incubation period of influenza virus [10]. The impact of an influenza
pandemic would be felt in the world economy as well. In 2007 the World Bank estimated
a cost of about three trillion dollars if a severe H5N1 pandemic were to occur [11].
Considering the frequency of travel and pace of society today, the world is especially
vulnerable to a new influenza pandemic. It is thus imperative to examine lessons from the
past to learn what factors contributed to the emergence of pandemic strains and to
aggressively pursue all avenues for prevention.
In this chapter I will introduce influenza A viruses, the human immune response to
influenza infection and vaccination, and the evolutionary arms race that takes place
between the virus and host’s immune system. Finally, I will discuss the current state of
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influenza vaccines and the efforts that are currently being made to improve seasonal
vaccine effectiveness and to provide protection against pandemic influenza strains.
Section 1.2 - Influenza A virus: tropism, structure, and replication
The Orthomyxoviridae family of viruses includes several Influenza genera, though
only Influenza A (IAV) and Influenza B (IBV) circulate in humans [12]. Aquatic birds are
the primary reservoir for influenza A viruses [13]. Avian IAVs infect the epithelial cells of
the gastrointestinal tract and are transmitted via the fecal-oral route [13]. In contrast,
human IAVs are transmitted via the respiratory route, where the epithelial cells of the
airway and lung are infected [14]. Influenza infection, and subsequent immune cell
infiltration, cause lung inflammation and alveolar epithelial injury that can eventually lead
to failure of gas exchange [15, 16]. The considerable lung trauma caused by IAV infection
may ultimately lead to acute respiratory distress syndrome (ARDS) or even death [17, 18].
IAVs are enveloped with a segmented, negative-sense, single stranded RNA
(ssRNA) genome of approximately 14 kilobases [19]. The eight ssRNA genomic segments
of IAV are associated with viral proteins; the RNA segments are coated in nucleoprotein
(NP) [20], while the heterotrimeric viral RNA polymerase (PB1, PB2, and PA) binds the
ends of the viral RNA [21]. The viral ribonucleoprotein (vRNP) complex is coated by the
M1 matrix protein [22], which is in turn enveloped by the host-cell derived lipid membrane
layer. The viral membrane is decorated with glycoprotein spikes of hemagglutinin (HA)
and neuraminidase (NA) in a ratio of about 4:1 [23], as well as a small number of matrix
ion channels (M2) that span the lipid membrane (M2:HA ratio of about 1:100-1000) [24].
Influenza A viruses are categorized according to the identity of their cognate HA and NA
proteins [25], which can be subtyped into at least 18 HA and 11 NA serotypes [26-28]. The
18 HAs can be further categorized into two genetically and antigenically distinct groups
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[29, 30], with group 1 containing H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and
H18, whereas group 2 encompasses H3, H4, H7, H10, H14, and H15 (Figure 1.1). The
sequence homology within a single HA subtype is estimated to be greater than 90%,
between subtypes in a single group is about 60-74%, and between groups the homology
drops to about 40-44% [31-33].

The HA protein forms a homotrimer of ~250 kDa [34, 35] that contains two distinct
functional domains: the membrane distal head and the membrane proximal stalk (Figure
1.2). The HA head mediates attachment of influenza virions to the host cell by binding to
glycan structures containing a terminal sialic acid through the receptor-binding site [36,
37]. The linkage of the glycan structure’s terminal sialic acid is considered to be a
determinant of host species specificity, with avian viruses characterized by binding α2,3linked sialic acid and mammalian viruses typically binding α2,6-linked sialic acid [38-52].
The HA preference for sialic acid linkage is directed in part by structural features within

4

the receptor binding site, and
is thought to correlate with
receptor availability within
the host species [16, 53, 54].
The

HA

stalk

domain

contains the fusion peptide
buried

within

hydrophobic

core

the
of

the

globular HA protein [55, 56]. Membrane fusion is triggered by decreasing pH within the
endosome as virions are trafficked into the host cell. When the pH reaches ~5.5-5.0 [57],
the HA protein undergoes a dramatic conformational change: the HA1 membrane distal
domains retain their pH-neutral structure but dissociate from each other [58-60], while the
fusion peptides in the HA stalk domain are transferred to the membrane-distal region after
loop-to-helix (AAs 55 and 76) and helix-to-loop (AAs 106 and 112) transitions within HA2
[56]. This conformational rearrangement is required for viral-endosomal membrane fusion
and subsequent entry of the viral genome into the host cytoplasm [61-64].
Once membrane fusion occurs, the vRNP is transported into the host nucleus
where transcription is initiated with the viral RNA polymerase [65]. Newly synthesized
mRNAs are used for translation of viral proteins, followed by synthesis of first
complementary RNA (cRNA), then viral RNA (vRNA) that is subsequently coated in NP
and M1 [66]. The newly synthesized viral proteins and vRNA are then trafficked to the
apical membrane of polarized host epithelial cells, where assembly and budding of
nascent virus occurs [66]. As the nascent HA and NA proteins are trafficked to the cell
surface they are post-translationally modified by host cell machinery to achieve their final
glycosylated and fully mature structures [66].
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To produce an infectious virion capable of membrane fusion, the immature HA
(HA0) protein must be cleaved into HA1 and HA2 subunits that are linked by disulfide
bonds [67-69]. The host proteases that can cleave HA0 are determinants of viral
replication sites, as they are only expressed in certain tissues, such as the mucosa of the
gastrointestinal and respiratory tracts [70]. Human IAVs encode for a monobasic cleavage
site in the HA0 protein that can be processed by several different cellular proteases found
in human respiratory epithelial cells, including transmembrane protease serine S-1
member 2 (TMPRSS2) and human airway trypsin-like protease (HAT) [71, 72]. TMPRSS2
is expressed in the trans-Golgi network, where it can cleave the HA0 protein as it is
trafficked to the cellular membrane. The M2 ion channel may assist in the prevention of
premature activation of the mature, fusogenic HA protein by equilibrating the slightly acidic
pH of the Golgi network [73, 74]. HAT is localized to the cellular membrane, where it can
cleave HA0 on nascent virions as they bud from the infected host cell [75, 76]. Conversely,
highly pathogenic avian IAVs contain a multibasic cleavage site that can be cleaved
intracellularly in the trans-Golgi compartment by proteases such as furin [77]; the
ubiquitous expression of these intracellular proteases contributes to a systemic, lethal
infection with up to a 100% mortality rate in poultry [78, 79].
As the nascent IAVs bud from the cell surface, their release is dependent upon the
sialidase activity of NA. The NA protein is a homotetramer with a membrane-distal globular
head domain [80] that contains a catalytic tyrosine residue within a highly conserved active
site on each monomer [81]. NA removes the terminal sialic acid from cell surface glycans
through hydrolysis of the glycosidic linkage [82-84]; this action facilitates the release of
budding viruses by preventing HA from binding to sialic acid at the cell surface [85, 86].
NAs encoded by human IAVs appear to have a general preference for α2,3-linked sialic
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acid and variable abilities to cleave α2,6-linked sialic acid [80, 87, 88]; however, in-depth
studies of NA sialic acid preferences are still lacking.

Section 1.3 - Human immune responses to influenza infection
The human immune response to influenza infection is a highly interconnected and
complex system, making it impossible to examine a single component without
consideration of many influential factors. Here, I will briefly cover the highlights of the
innate immune response and contributions of CD8+ and CD4+ T cells to protection against
IAV infection. I will then go into greater detail about the activation of B cells and production
of high-affinity, IAV-specific antibodies.
Innate immunity
The innate immune system acts as the first line of defense against IAV infection.
Human respiratory epithelial cells detect pathogen associated molecular patterns
(PAMPs), such as IAV RNA, through a variety of receptors. Detection of PAMPs initiates
signaling pathways that lead to the secretion of type I and type III interferons (IFNs), proinflammatory cytokines, eicosanoids, and chemokines. Type I IFNs induce the expression
of hundreds of IFN-stimulated genes to aid in protecting neighboring cells form infection
[89-96]. The pro-inflammatory cytokines and eicosanoids induce inflammation, fever, and
influence the adaptive immune response. Secreted chemokines work to recruit myeloid
and lymphoid cells, such as neutrophils and natural killer (NK) cells, to the site of infection
to aid in the clearance of virus-infected cells to inhibit viral replication and spread [97, 98].
Dendritic cells (DCs), located within the respiratory tract and secondary lymphoid
tissues [99, 100], act as the bridge between the innate and adaptive immune responses.
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Antigen-loaded DCs migrate to secondary lymphoid structures where they activate naïve
T cells and promote a polarized T helper 1 (TH1) cell response through the secretion of IL12 [101]. The characteristic TH1 cytokine, IFN-γ, acts on DCs to further enhance antigen
presentation during the T cell priming process [102] and upregulation of MHC class II
expression [103]. The TH1 polarization mediated by DCs has other downstream effects
important for responding to influenza virus infection, including induction of antibody
isotype-switching [104, 105].
CD8+ T cells
Naïve CD8+ T cells are activated by DCs in the draining lymph node, leading to
proliferation and differentiation into cytolytic CD8+ T cells. Activated CD8+ T cells then
migrate back to the lungs where they induce apoptosis in IAV-infected cells through potent
cytolytic responses [106]. Although CD8+ T cells cannot prevent an infection from
occurring, they do play a crucial role in the control of, and recovery from, influenza infection
[107-109]. Memory CD8+ T cells are capable of heterosubtypic protection upon
subsequent infection, as they typically target epitopes in the more conserved internal IAV
proteins [110, 111]. This cross-reactivity offers the potential for broad immunity against
diverse influenza strains as long as the established memory CD8+ T cell population
survives. Murine models have demonstrated lifetime persistence of influenza-specific
CD8+ T cells [112, 113], and recent studies in humans have detected epitope-specific
CD8+ T cells by ex vivo tetramer staining over a 13-year time period [114].
CD4+ T cells
Similar to CD8+ T cells, influenza-specific naïve CD4+ T cells interact with antigenpresenting DCs in secondary lymphoid tissues. Activated CD4+ T cells proliferate and
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begin to differentiate, acquiring effector functions and producing cytokines to direct other
immune functions. In primary influenza infections, CD4+ T cells indirectly mediate viral
clearance by promoting antibody production by B cells [115-118] and enhancing
recruitment of naïve CD8+ T cells to the lymph node [119] for interaction with antigenloaded DCs [120, 121]. CD4+ T cells are important in the priming and establishment of
the memory CD8+ T cell compartment [122]. Additionally, memory CD4+ T cells likely play
a role in the recruitment of early innate effector cells to the lung [123, 124], promoting
effector mechanisms to blunt the early stages of IAV infection and replication [125]. Finally,
a cytolytic subset of CD4+ T cells are enriched in lung tissue during influenza infection
[126-130], suggesting functional CD4+ T cells may also mediate direct control of viral
replication and spread in the respiratory tract.
B cells
The humoral adaptive immune response is essential for protection against
reinfection by a multitude of pathogens, each with their own unique molecular structures
that must be recognized for appropriate response and subsequent protection. The
adaptive immune response of vertebrates combats this daunting molecular diversity of
pathogens with a comparable level of diversity amongst antibodies. B cells express
antibodies that are composed of heavy and light chains that are randomly assembled
through a genetic rearrangement process called VDJ recombination, generating
tremendous structural diversity [131]. Mature B cells express B cell receptors (BCRs) on
their cell surface that are encoded for by these rearranged antibody gene segments.
During an immune response to influenza infection, B cells specific for influenza antigens
are activated by the interaction between their BCR and cognate antigen. B cells encounter
influenza antigens in specialized lymphoid structures called germinal centers that are
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present in the lymph nodes and spleen [132]. CD4+ T cells are also present in these
germinal centers and provide help to activated B cells to undergo proliferation, classswitching, and somatic hypermutation of the variable region of the heavy and light chain
genes to generate variants. These B cell variants then undergo clonal selection by
competing for antigen binding through a process called affinity maturation, resulting in a
high-affinity polyclonal antibody response [133]. These high-affinity, class-switched B cells
can go on to become long-lived plasma cells or memory B cells. During a secondary
immune response, memory B cells can be recalled and undergo additional rounds of
somatic hypermutation and affinity maturation [134]. Recruitment of influenza-specific
memory B cells during secondary immune responses has important ramifications for
antibody-mediated immunity, which will be discussed in detail later.
Antibodies
All IAV proteins are potential targets for a protective antibody response, but not all
are easily accessible to antibodies. HA and NA are present on both viral membranes and
the surface of infected cells, making them the most abundant and easily accessible targets
[135]. Typically, HA induces the largest antibody response, with about 25-52% of
plasmablasts binding to HA after an infection, while NA accounts for about 14-35% of IAVinduced plasmablasts [136]. Anti-NA antibodies can block the enzymatic cleavage of sialic
acid by NA [136], a function that is required for IAVs to successfully infiltrate mucosal
surfaces and for the release of nascent viruses as they bud from cells [137]. NA antibodies
have demonstrated protection against IAV lethal challenge in animal models [138-140],
can prevent transmission of virus in guinea pigs [141], and are associated with protection
in human field and challenge studies [142, 143]. In addition to the viral membrane proteins,
internal IAV proteins, such as NP, may become accessible to antibodies when they are
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displayed on the membrane of an infected cell, or after an infected cell has died [144].
Non-neutralizing antibodies targeting NP have been identified as contributing to protection
against lethal influenza infections in mice [145].
The HA protein is the major target of neutralizing antibodies and is the focus of this
thesis. Therefore, the remainder of this chapter will focus exclusively on the HA protein
and HA-specific antibody-mediated protection. Antibodies targeting the HA head have
historically been the hallmark for measuring vaccine efficacy and levels of pre-existing
immunity in the human population [146]. Additionally, by interacting with their innate
cellular partners, some HA stalk-specific antibodies mediate broad, cross-subtype and
cross-group protection against IAVs [147, 148].
HA Head Antibodies
The HA head domain is the immunodominant target for antibodies elicited by IAV
infection and vaccination. Antibodies that target the HA head can prevent IAV entry into
the host cell by binding at or near the receptor binding site (RBS). Antibodies binding within
or near the RBS can block virus binding to sialic acid and/or prevent receptor-mediated
endocytosis [149-151]. Antibodies elicited against the HA head domain are usually strainspecific, and therefore only confer homosubtypic protection [152-155]. This limited breadth
of protection can be explained by the selective pressure exerted by the immune system,
which gives rise to new strain variants that can evade previously elicited antibodies; this
process is called antigenic drift and will be covered in detail later.
HA Stalk Antibodies
The HA stalk is immunosubdominant to the HA head; antibody responses against
this domain typically constitute a small fraction of the overall antibody response against
influenza

in

humans

[148].

The

exact
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cause

of

the

HA

stalk

domain’s

immunosubdominance has not yet been determined. One proposed hypothesis is based
on the concept of steric hindrance [156], or limited access to HA stalk epitopes. Shielding
of the HA stalk domain by the HA head or other surface proteins is plausible, as the IAV
membrane is tightly packed with the surface glycoproteins HA and NA, with an average
packing density of about 375 glycoproteins per virion, resulting in an average of 11 nm
spacing between each glycoprotein spike [157]. It has also been postulated that the HA
stalk domain may be inaccessible due to its proximity to the viral membrane, based on the
observed bias of the hydrophobic VH1-69 immunoglobulin gene usage within humans to
encode for HA stalk-reactive antibodies [158-161]. However, recombinant HA vaccines
have failed to elicit robust HA stalk antibody titers [162] and cryoelectron tomography has
demonstrated that the majority of HA proteins on influenza virions are available to stalkspecific antibodies [163], suggesting that steric hindrance is not an issue. An alternative
hypothesis proposes B cells specific for HA stalk epitopes are under negative selection,
based on the observation that HA stalk antibodies can be polyreactive [156], which may
contribute to HA stalk antibody immunosubdominance.
Despite the issue of immunosubdominance, HA stalk antibodies are often broadly
cross-reactive, due to the high conservation of the stalk domain within and across
influenza subtypes, and they are able to mediate protection through a variety of
mechanisms. Monoclonal antibodies (mAbs) have been isolated from humans that bind a
conformationally-dependent epitope that spans the HA1-HA2 interface, thus locking the
HA into its pre-fusion form to block pH-induced viral-endosomal membrane fusion [58,
147, 148, 164, 165], to inhibit viral egress [164] or to prevent HA0 maturation [165]. A new
mechanism of HA stalk antibody-mediated protection was recently described, whereby
steric hindrance from bound HA stalk antibodies prevent the enzymatic activity of the viral
membrane protein NA [166]. Additionally, many broadly neutralizing HA stalk antibodies
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mediate protective mechanisms by coupling antigen binding with Fc-mediated effector
function [167, 168]. Fcγ receptors (FcγRs) are a major regulatory component of the
immune system that couples innate and adaptive immunity. Many immune cells express
both activating and inhibitory FcγRs; the paired expression and signaling of these
receptors is required for establishing a balanced immune response [169]. Additionally,
FcγRs have varying affinity for individual antibody isotypes, rendering an additional layer
of regulatory control over Fc-mediated effector functions [170, 171].
HA stalk antibodies have demonstrated the ability to induce all of the Fc-receptor
mediated functions that have long been known to play a role during influenza infection and
vaccination [172]: antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent
cellular phagocytosis (ADCP), and antibody-dependent complement-mediated lysis
(ADCL). ADCC is induced when the Fc domain of IgG1 or IgG3 antibodies bind the HA
stalk, presented on the surface of infected cells, and simultaneously engage the FcγRIIIA
(CD16) found on NK cells, monocytes/macrophages, and neutrophils [172]. CD16 signals
through ITAM to activate downstream calcium-dependent signaling pathways that
culminate in the release of granzyme B and perforin, facilitating DNA fragmentation and
apoptosis of the infected target cell [131]. ADCP is induced by HA stalk antibodies
opsonizing the surface of influenza-infected cells or by forming immune complexes. The
Fc-domain of these antibodies then interact with innate phagocytic immune cells bearing
either FcγRIIb (CD32) or FcγRI (CD64), predominantly engaged by IgG1 or IgG3, or FcαRI
(CD89), engaged by IgA, inducing uptake of the infected target cell or immune complex
[131, 173, 174]. ADCL is initiated when the Fc domain of antibodies (IgG1 or IgG3) bound
to the HA stalk, expressed on the cell surface of infected cells, recruits the C1q protein
[175-178]. Binding of C1q triggers the complement cascade and formation of the
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membrane attack complex at the surface of the infected cell, inducing cell lysis and a
proinflammatory environment [131].
It is important to note that HA stalk antibodies should not be categorized as those
that “neutralize” or those that “mediate Fc effector functions”; rather, many HA stalk
antibodies seem to have a number of functions (both direct and indirect) available to them,
given their specific isotype and ability to engage Fc receptors [179, 180]. Some of the
factors that have been shown to impact Fc receptor engagement are concentration,
isotype, binding specificity, and Fc glycosylation [172]. Additionally, recent work suggests
that HA stalk antibodies require the HA to be bound to sialic acid for optimal activation of
effector cells through Fc-receptor interactions [181].

Section 1.4 - Unique challenges for influenza immunity
For many viruses, elicitation of a neutralizing antibody response will confer lifelong immunity. However, influenza viruses and the host immune response to IAV
infection/vaccination present some unique challenges that prevent the development of
complete immunity.
Antigenic drift
The error-prone RNA polymerase of influenza virus plays an essential role in
facilitating antigenic drift, whereby population immunity to IAVs drives the process of
selecting antigenic variants in HA and NA that contain substitutions which abrogate
binding of pre-existing antibodies [5, 182, 183]. Due to the selective advantage of immuneescape, drifted viruses dominate circulation [184-186] and the amino acid substitutions
become fixed in circulating influenza strains. Antigenic drift facilitates continuous
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circulation of seasonal influenza virus strains within the human population, undermining
seasonal vaccine efficacy and causing considerable morbidity and mortality [187].
Why do we have effective vaccines for other RNA viruses, but not for influenza
viruses? Similar to influenza viruses, measles virus is also an RNA virus with an errorprone RNA polymerase and subsequently high mutation rate. However, unlike influenza
viruses, infection with measles viruses protects against reinfection, and vaccination with
either the combined MMR (measles, mumps, rubella) or the stand-alone measles vaccine
provides 99.7% of people with complete, lasting immunity to measles infection [188].
Additionally, the measles vaccine has remained highly effective against currently
circulating measles viruses, indicating that viral escape from vaccine-induced immunity
has not occurred [189]. While the RNA polymerase of measles virus is also error-prone,
the surface proteins of measles (the target of human immunity) are highly intolerant of
mutations [190]. Therefore, while mutations are likely introduced into the measles genome
at a rate similar to that of influenza, the inelasticity of the surface glycoproteins may
contribute to the observed lack of antigenic variation, as antigenic variants are unable to
replicate well [190]. The result is a virus that is restricted to its original genetic identity,
making a stable target for antibodies elicited from a single round of vaccinations [190]. In
contrast, the surface proteins of influenza virus are exquisitely tolerant of mutations
introduced by the error-prone RNA polymerase [191]; this allows for a single mutational
“parent strain” to proliferate and their progeny to acquire new and different mutations,
ultimately resulting in the phylogenetic diversity of influenza viruses circulating today.
It is important to note that not all genetic changes in HA affect antigenicity. Amino
acid substitutions can also be selected to fine-tune HA function, to compensate for other
substitutions to maintain viral fitness, or simply be the result of the error-prone polymerase
in regions of the protein that are not antigenically important. Determining the functional
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consequences for individual substitutions is fundamental to understanding how influenza
viruses evade host immune responses and to designing better vaccines. I will be covering
this in greater detail in Chapters 3 and 4.
Antigenic shift
Antigenic shift occurs when a novel influenza viral strain enters a human
population for the first time. Circulating influenza viruses are incredibly diverse and are a
significant source of zoonotic infection. The diversity is due in no small part to the
segmented genome of influenza viruses, which facilitates recombination between strains.
Cells that are co-infected by viruses of different subtypes can swap genomic segments,
generating new viral variants that can have altered virulence and/or antigenic properties
[192]. By swapping genetic segments, a novel influenza virus can arise that contains
highly pathogenic attributes and the transmissibility from other viruses that previously
circulated in humans [192]. Importantly, viral reassortment can result in zoonotic spillover
events, allowing viral variants to jump from circulation in one species into another species
[193].
The influenza pandemics of 1957 (H2N2), 1968 (H3N2), and 2009 (H1N1) were
the result of reassortment events between avian, swine, and human influenza strains [194197]. The burden of zoonotic spillover events, with their potential to cause pandemics, has
attracted global attention since it was identified that influenza A viruses of both avian and
swine origin can be directly transmitted to humans. This direct transmission was especially
notable with the H5N1 lineage (A/Goose/Guangdong/96) that infected 860 people and
caused 454 deaths through December 2017 [198]. Thus far, sustained human-to-human
transmission of H5N1, or H7N9 (a group 2 influenza virus that has caused significant
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mortality rates in isolated outbreaks) [199], have not been detected, but represent potential
pandemic strains that are poised to jump directly into human circulation.
Reverse zoonosis (human to animal transmission) also poses a significant
pandemic threat. Pigs might be an important “mixing vessel” for the emergence of
potentially pandemic reassortment viral variants due to their susceptibility to most
influenza A strains and because their respiratory tract contains the receptors for both avian
and mammalian influenza stains (α2,3- and α2,6-linked sialic acid, respectively) [193].
Since 2009, repeated reverse zoonosis of the human pH1N1 strain into pigs has
contributed to the expansion of the genetic diversity of swine influenza A viruses [200].
Potential pandemic strains have emerged from these reassortment events, such as the
H3N2v swine IAV that infected more than 300 humans in the United States during 20112013 [201].
The continuous reassortment and spillover events make it increasingly difficult to
predict what influenza strains may cause the next influenza pandemic. Determining what
molecular evolutionary changes allow certain influenza strains to jump between host
species remains an important question in influenza research and is crucial for the
development of prevention measures.
Immune imprinting
Influenza immunity has an additional layer of complexity that has been observed
since the 1950s: while antibodies elicited by a primary influenza virus exposure are highly
strain-specific, antibodies elicited by an antigenically distinct, secondary influenza
exposure tend to be highly cross-reactive with the first strain [202-204], but may be poorly
reactive to the second strain [205, 206]. This phenomenon was originally described as
‘original antigenic sin’ by Thomas Francis, Jr, referring to the notion that an individual’s
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immune system will bear the “sin” of their very first childhood exposure to influenza, and
that this will influence the antibody response to all subsequent influenza exposures [204].
However, this phenomenon should not be misinterpreted as a strictly deleterious
consequence of sequential influenza virus exposures. Indeed, the contemporary phrasing
of ‘antigenic seniority’ [207] or ‘immune imprinting‘ [208] may more accurately represent
the immune system’s ability to develop high-affinity, cross-reactive antibody responses
over time through the sequential exposure of antigenically distinct viral strains.
While the exact mechanisms behind ‘original antigenic sin’ have not been fully
elucidated, the concept refers to the propensity of the immune system to preferentially
recall memory B cells that target antigenic epitopes conserved between primary and
subsequent influenza virus exposures [209, 210]. Multiple mechanisms may influence this
preferential recall of memory B cells. First, the availability of antigen for strain-specific
naïve B cells is likely diminished due to previously established immune responses in the
form of broadly neutralizing antibodies, effector functions induced by cross-reactive
antibodies (ADCC, ADCP, etc), and cytotoxic T cells [211, 212]. The second contributing
mechanism is a competition for antigen access between naïve B cells reactive to novel
epitopes of secondary influenza strains and memory B cells that have higher antigen
avidity and a lower threshold of activation [213]. The higher avidity of memory B cells
confers a competitive advantage over naïve B cells for access to antigen and signaling
from T follicular helper (TFH) cells, increasing the likelihood of a memory response over a
de novo response. When memory B cells are recalled, they re-enter a period of clonal
expansion and somatic hypermutation to generate a high affinity antibody response
against the new viral strain [214], resulting in an immune repertoire that gradually
increases its concentration of highly cross-reactive antibodies that target conserved,
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subdominant epitopes as the host ages and is sequentially exposed to antigenically
distinct viral strains [156, 215].
Immune imprinting was evident during the 2009 H1N1 pandemic. The pH1N1 HA
amino acid sequence was 27.2% different from the human H1N1 HA circulating in 2008
[216]. However, the HA stalk remained relatively well conserved, resulting in the
preferential boosting of HA stalk antibodies in many adults [217-219]. Other studies
identified individuals with immune responses focused on a rare HA head epitope that was
conserved from the seasonal H1N1 (sH1N1) strain that had circulated during their
childhood [220-223]. Importantly, the ability to skew antibody responses towards epitopes
conserved between sH1N1 and pH1N1 strains were recapitulated in ferrets after
sequential infection with a 1991 sH1N1 virus and the 2009 pH1N1 virus [221]. Taken
together, these studies demonstrate that the host’s year of birth influences the antibody
response for a given influenza infection.
It has become increasingly clear that individuals recall memory B cells that target
HA epitopes conserved amongst subtypes within both group 1 and group 2 influenza A
viruses [224-226], and that immune imprinting is important for pandemic virus
susceptibility. This is consistent with an epidemiological study from Gostic et al, who
demonstrated a correlation between the probability of first influenza exposure to either a
group 1 or group 2 HA (based on year of birth and circulating seasonal influenza strains)
and susceptibility to avian H5N1 and H7N9 influenza strains [208]. They found that
individuals primed with a group 1 HA appeared to be protected from H5N1 (group1 HA,
Figure 1.1) but susceptible to H7N9 (group 2 HA, Figure 1.1). Conversely, individuals
primed with a group 2 HA appeared to be protected from H7N9, but susceptible to H5N1.
All individuals were likely exposed to both group 1 and group 2 HAs throughout their life,
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given normal seasonal circulation, suggesting that the first infection that an individual
encounters is the most important for establishing long-lived immune memory.
The apparent heterosubtypic protection observed in the Gostic study is likely
mediated by HA stalk antibodies. The majority of broadly neutralizing antibodies target
epitopes in the HA stalk domain as this domain is highly conserved across influenza
strains [147, 148, 227]. Broadly neutralizing HA stalk antibody responses are induced
following natural influenza infection [218, 228, 229] and can be boosted through
vaccination by HAs with antigenically distinct head domains [230-236]. The ability to
induce a neutralizing, cross-reactive antibody response is currently being explored as a
tool to improve seasonal influenza vaccine efficacy and to mitigate the impact of a future
influenza pandemic, as will be described below.

Section 1.5 - Correlates of protection
The CDC estimates the effectiveness of seasonal influenza vaccines through
several surveillance networks that perform observational studies to assess how well the
influenza vaccine is working that year to prevent infections, medical visits, and
hospitalizations [4]. The effectiveness of the vaccine is determined by comparing the
frequency of vaccinated versus unvaccinated individuals with PCR-confirmed influenza
infections [4]. The identification of a true correlate of protection – a test that can accurately
predict the effectiveness of a vaccine – is one of the ‘holy grails’ of vaccine development
[237, 238]. Typically, serological assays are performed to measure surrogate markers for
immunity and protection [239].
For influenza, measurement of HA head antibodies has historically been the gold
standard for determining seroconversion and immunogenicity in vaccine studies.
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Hemagglutination inhibition (HAI) assays measure the presence of antibodies in the serum
to prevent agglutination of red blood cells, mediated by HA binding to sialic acid that
decorates the surface of the red blood cells. The HAI antibody titers are then used as a
proxy for the ability of antibodies to inhibit viral receptor binding [240, 241], with an HAI
titer of >1:40 considered a surrogate marker for approximately 50% protection against
influenza infection [241, 242]. HAI titers are widely used as a surrogate of protection and
have been included in vaccine licensure requirements by several regulatory authorities
[243, 244], resulting in vaccine development that focused on elicitation of high HAI titers.
Unfortunately, this threshold is far less predictive of protection in children and the elderly
[245, 246], and does not provide any information about antibodies that may neutralize
through mechanisms other than inhibition of receptor binding.
In an effort to address this shortcoming, microneutralization (MN) assays have
been used in recent years to measure the ability of antibodies to inhibit viral infection and
replication in cell culture [247]. This technique detects functional antibodies that directly
neutralize the ability of a virus to enter a host cell or to replicate/spread, and therefore
detects antibodies against all viral proteins [248]. However, no correlates of protection
have yet been defined for MN titers, making it difficult to compare to HAI assays and
assessments for vaccine effectiveness [249]. Additionally, the complexity of this assay
increases the risk of inter-laboratory variability, though the inclusion of antibody standards
has increased reproducibility [250].
In

addition

to

traditional

immunological

techniques,

the

enzyme-linked

immunosorbent assay (ELISA) is a commonly used assay to detect anti-influenza
antibodies [251]. The advantages of this technique are that it is suitable for large-scale
serological investigations, is reproducible with readily available standardized reagents,
and can be used to detect protein-specific antibody subsets (through the use of purified,
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recombinant proteins) and/or individual antibody isotypes [239, 252-255]. The primary
disadvantage of an ELISA is that it only measures the prevalence of antibodies, regardless
of their functionality. This caveat likely contributes to the lack of an ELISA-based correlate
of protection being established yet.
However, the human immune response is a highly interconnected and dynamic
system that does not operate in a vacuum, and important subsets of neutralizing
antibodies may be missed by these traditional immunological techniques. T cell-mediated
immunity and effector functions mediated by Fc-receptor interactions with antibodies are
important contributors to protection and should be evaluated accordingly. As I will discuss
in detail later, vaccines are currently being developed to elicit broadly neutralizing HA
stalk-specific antibodies with direct and indirect functionality that may not be detected by
these traditional assays. It is therefore imperative that assays be developed to detect
these unique antibody subsets and correlates of protection using these assays be
established.

Section 1.6 - Seasonal influenza vaccines
IAV was first isolated from the nasal secretions of infected human patients in 193233 [256], followed quickly by the discovery that influenza A viruses could be grown in the
allantoic fluid of embryonated chicken eggs in 1935 [257]. Over the next five years the
process for developing influenza vaccines was elucidated - from the immunogenicity of
formalin-inactivated virus to the purification of viruses harvested from embryonated
chicken eggs by high-speed centrifugation [258], a process that is still widely used to this
day.
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Influenza vaccines have been repeatedly transformed over the years to
accommodate the continual advancement in the fields of influenza virology and human
immunology. What began as an inactivated, monovalent preparation of only influenza A
in the early 1940’s has become a trivalent or quadrivalent preparation containing antigens
from one H1N1 strain and one H3N2 strain, combined with either one or two strains of
influenza B virus [259]. Generation of the vaccine components has also diversified – some
vaccines contain only a recombinant HA protein grown in insect cells and others contain
influenza virus grown in mammalian cell culture or embryonated chicken eggs;
additionally, whole virus preparations can be either chemically inactivated or be liveattenuated [260, 261]. However, the vast majority of seasonal influenza vaccines are still
produced by growing the virus in embryonated chicken eggs, chemically inactivating the
virus, then purification – the same procedure that was originally developed in the 1940s
[259].
The advent of global surveillance of circulating influenza strains has greatly
influenced the composition of antigens used in influenza vaccines. The first influenza
surveillance system, Global Influenza Surveillance and Response System (GISRIS), was
established by the World Health Organization in 1952 to monitor antigenic drift of
circulating viruses around the world [262]. The newly established surveillance system
provided an innovative tool that enabled the composition of influenza vaccines to be based
on the epidemiology of circulating influenza viruses from the previous season.
The strains included in the seasonal vaccine must be updated frequently to adjust
for the antigenic substitutions that confer escape from antibodies boosted by vaccination.
Through the GISRIS centers, circulating influenza strains are isolated from infected
individuals, sequenced, and antigenically characterized. To determine whether antigenic
changes have occurred in circulating strains that confer escape from vaccine-induced
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immunity, ferrets are infected with the vaccine strain [263]. The ferret antiserum, and in
recent years human serum [264], is tested by various serological assays to screen for
antigenic differences between previous vaccine strains and circulating strains. If the tested
sera demonstrates poor inhibition of hemagglutination, the vaccine strain is generally
updated [263]. To update the vaccine strains, the HA and NA genes from some of the viral
isolates are incorporated into high-growth reassortant strains using the six internal gene
segments of the culture-adapted virus A/Puerto Rico/8/1934 (PR8). From these highgrowth reassortant strains, candidate vaccine viruses (CVVs) are selected and are
recommended for use as seed strains to influenza vaccine manufacturers.
Our current system for seasonal vaccine strain selection and production provides
ample opportunity for antigenic mismatch to occur between the selected vaccine strain
and the circulating strain. The vast majority (~82%) of influenza vaccines were produced
in chicken eggs for the 2019-2020 influenza season [265]. Influenza viruses must adapt
for growth in chicken eggs to accommodate the α2,3-linked sialic acid present on avian
cells, often resulting in amino acid substitutions at or near the receptor binding sites of HA
[266]. Human influenza viruses acquire HA substitutions that improve binding to α2,3linked sialic acid when grown in chicken eggs, but these substitutions have the potential
to cause an antigenic mismatch between the vaccine and circulating strain [267, 268].
The timeline required for producing enough influenza vaccine doses is another
contributing factor towards the occurrence of antigenic mismatch. One embryonated
chicken egg produces enough virus for approximately one vaccine dose; with
approximately 162 million doses of vaccine projected to be produced and distributed within
the United States for the 2019-2020 influenza season alone, this requires a demanding
production schedule [265]. To meet this production deadline, vaccine manufacturers must
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begin production in the Northern Hemisphere immediately after vaccine strain selection is
announced in February, even though vaccine doses aren’t distributed until September or
October. During the 8-9 month interim between strain selection and vaccine distribution,
antigenically distinct strains containing novel substitutions can emerge, resulting in an
antigenic mismatch between the vaccine and circulating influenza strains [269].
When antigenically drifted strains circulate during an influenza season, vaccine
efficacy can be greatly reduced, as evidenced by the 2014-2015 influenza season when
there was an antigenic mismatch between the vaccine and circulating influenza strains
[270]. The population vulnerability that is imposed by our current vaccine production
system is especially evident when an influenza pandemic occurs. During the 2009 H1N1
pandemic the vaccine containing the new pandemic strain arrived too late to prevent the
majority of infections that occurred [271]. Indeed, it was our vulnerability during the 2009
H1N1 pandemic that imbued a sense of urgency in the pursuit of a better influenza vaccine
- a vaccine that not only protects against antigenically drifted seasonal strains, but also
against future pandemic strains.

Section 1.7 - Pursuit of a universal influenza vaccine
A universal influenza vaccine would be one that confers protection against all
HA/NA subtypes of influenza A viruses, independent of antigenic drift. To achieve this, a
vaccine must be designed that redirects the human immune response towards a highly
conserved viral target that can elicit broadly neutralizing antibodies. Several targets for
universal influenza vaccines are currently being explored, including the HA stalk domain
[272-275], NA [276], the ectodomain of the M2 ion channel [277], as well as the internal
proteins NP and M1 [278, 279].
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The HA stalk domain has become one of the more promising targets in the
development of a universal influenza vaccine, with two different platforms currently in
clinical trials (discussed below). The HA stalk domain is an appealing target because it is
relatively intolerant to change [191, 280-282] and is highly conserved across influenza
strains, with some central residues being 100% identical across all subtypes [147, 148,
227]. Three protective epitopes have been identified with varying levels of cross-reactivity
between influenza A strains (Figure 1.3). Epitope 1 is located on the A a-helix of HA2.
Antibodies that target this domain confer the broadest protection, as this epitope is
conserved across Influenza A groups 1 and 2 [147, 148, 217, 283, 284]; however,
antibodies that target this epitope must have unique characteristics to accommodate the
glycan modifications that can obscure this epitope across influenza strains [283]. Epitopes
2 and 3 are conserved between group 2 influenza A subtypes; epitope 2 spans the upper
portion of the long CD alpha helix in HA2 [285] and epitope 3 contains the fusion peptide
and helix-capping loops at the base of the HA stalk [286]. Induction of a robust antibody
response against these conserved epitopes, particularly epitope 1, would confer broader
and more durable protection against influenza infection by circumventing our current
reliance on epitopes subject to antigenic drift.
Humans have an extensive immune history with influenza, both through
vaccination and natural infection. The resulting memory B cell repertoire is the primary
source of HA stalk-specific antibodies, based on the extensive mutation load and binding
affinity found within this compartment [156, 217, 218]. Additionally, the onset of the 2009
H1N1 pandemic revealed that many individuals did not seroconvert for HA head
antibodies post-infection or post-vaccination [218, 219]; rather, memory B cells for
conserved epitopes within the HA stalk domain were preferentially recalled, inducing a
more broadly neutralizing antibody response [218, 287]. Therefore, development of a
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universal influenza vaccine that is designed to capitalize on the pre-existing memory B
cells against the HA stalk domain would seem a reasonable path forward. However, it is
difficult to elicit HA stalk-specific responses from traditional vaccine approaches due to the
immunodominance of the HA head domain [222]. To address this difficulty, HA stalkspecific vaccine platforms are being developed, two of which are currently being tested in
clinical trials.
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Chimeric HA vaccine
One approach is based on chimeric HAs (cHAs) composed of the H1, H3, or
influenza B HA stalk domains combined with the HA heads of ‘exotic’ influenza subtypes
that have not circulated in humans previously, usually from an avian influenza strain [288290]. The strategy is to sequentially vaccinate, using cHAs containing different head
domains for each vaccination. In this way, a de novo response is generated against the
exotic HA head, while a memory B cell response is boosted against the conserved HA
stalk, with each subsequent vaccination. This cHA vaccine approach has been tested in
both mouse and ferret models using the H1 stalk cHA (containing first an H5 head,
followed by an H8 head), and was found to protect from challenge with diverse influenza
viruses [291-294].
The c5/H1-c8/H1 prime-boost vaccine regimen has recently completed a phase I
clinical trial in a collaboration between Icahn School of Medicine Mount Sinai and
GlaxoSmithKline (GSK) to test the immunogenicity and safety of either a live-attenuated
or inactivated cHA sequential vaccine with and without the GSK adjuvant, AS03
(clinicaltrials.gov, NCT03300050). According to the interim report [272], the primary
vaccine (adjuvanted c5/H1 inactivated virus) induced a robust IgG response against the
H1 HA stalk, reaching a 7-fold increase above baseline titers by day 29 post-vaccination,
whereas the live-attenuated vaccine did not induce a strong anti-stalk response. Following
the booster vaccination (c8/H1), all vaccine regimens induced detectable H1 HA stalk IgG
responses that were cross-reactive; however, a strong memory B cell response was only
induced by the inactivated/adjuvanted prime vaccination. At the time of this writing, final
results from this trial have not been published.
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Headless HA stalk nanoparticle vaccine
The second strategy to elicit HA stalk-specific antibody responses comes in the
form of a nanoparticle coated in ‘headless’ HA stalk constructs. While the development of
a stable, conformationally intact ‘headless’ HA stalk is challenging, constructs have been
successfully generated for both group 1 [273, 275] and group 2 [274] influenza A viruses.
This strategy has the advantage of removing the immunodominant head altogether,
allowing for an exclusively HA stalk-focused immune response to occur. Additionally, a
ferritin nanoparticle is used as the vaccine delivery platform, which allows multiple HA
stalk proteins to be displayed on its surface, mimicking the natural organization of HA on
an influenza virion. The H1 HA ‘headless’ stalk nanoparticle has demonstrated
heterosubtypic protection in both mouse and ferret models [273], and a clinical trial
(NCT03186781), testing a full-length H1 HA on the ferritin nanoparticle, demonstrated the
safety and tolerability of the nanoparticle platform in humans. The group 1 (H1) headless
HA stalk nanoparticle vaccine is currently in a clinical trial (NCT03814720) through the
Vaccine Research Center at the National Institute of Allergy and Infectious Diseases
(NIAID), though at the time of this writing the results have not yet been published.
Section 1.8 - Experimental questions
To achieve the goal of developing a universal influenza vaccine, we must identify
a viral antigen that is not only targeted by potent antibodies but is also conserved across
all HA subtypes and largely intolerant to antigenic drift. The HA stalk domain is largely
conserved between the HA subtypes, and antibodies against this domain have provided
heterosubtypic protection in numerous animal models. However, important questions
need to be answered before determining if an HA stalk-based universal influenza vaccine
will provide broad protection against seasonal and pandemic influenza strains. Are H1 HA
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stalk antibodies associated with protection against sH1N1 infection and/or severe disease
in humans? Can we establish correlates of HA stalk antibody-mediated protection? What
easily-standardized and reproducible assays should be developed to accurately predict
vaccine efficacy using a correlate of protection that functions through numerous
mechanisms of protection? Is the H1 HA stalk domain susceptible to antigenic drift, or is
it a stable target for long-term protection?
In Chapter 2, we utilize a human serological cohort to determine if H1 HA stalk
antibodies are associated with protection against H1N1 influenza infection and disease,
and to characterize this antibody subset. We demonstrate that HA head antibody titers are
independently associated with protection against influenza infection and confer potent
protection in vivo against viral challenge. We also show that HA stalk antibody titers are
associated with protection against human influenza infection, and that HA stalk antibodies
provided moderate protection in vivo against viral challenge of mice. Additionally, we
characterized the isotype composition and probed the functional features of the H1 HA
stalk antibody subset in human sera. This study demonstrates for the first time that human
HA stalk antibodies in polyclonal serum are associated with protection in adults and can
protect against H1N1 severe influenza disease in mice in the absence of HA head
antibodies.
In Chapter 3 we identify six amino acid substitutions in the H1 HA stalk domain
that have become fixed in circulating viral populations since 2009. Using a human
serological cohort, we demonstrate these amino acid substitutions have not decreased
the binding or affinity of antibodies in polyclonal sera in a biologically relevant manner,
indicating antigenic drift has not occurred in the H1 HA stalk domain for the entirety of this
subtype’s circulating history. This observation suggests that while the HA stalk is not
completely intolerant to change, these changes do not appear to alter the antigenicity of
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this protein. This study illustrates the durability of the HA stalk domain as a target for a
universal influenza vaccine approach.
Finally, in Chapter 4, I will discuss the implications of our findings for the pursuit of
an HA stalk-based universal influenza vaccine. I will also address how these results can
launch new investigations into the functionality and applicability of HA stalk antibodies for
future therapeutic and vaccine development.
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CHAPTER 2

ASSESSING THE PROTECTIVE POTENTIAL OF H1N1 INFLUENZA VIRUS
HEMAGGLUTININ HEAD AND STALK ANTIBODIES IN HUMANS

Parts of this chapter were previously published as:

Shannon R. Christensen, Sushila A. Toulmin, Trevor Griesman, Lois E. Lamerato, Joshua
G. Petrie, Emily T. Martin, Arnold S. Monto, Scott E. Hensley (2018). Assessing the
protective potential of H1N1 influenza virus hemagglutinin head and stalk antibodies in
humans. Journal of Virology 93 (8) e02134-18; DOI: 10.1128/JVI.02134-18.
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Section 2.1 - Abstract
Seasonal influenza viruses are a major cause of human disease worldwide. Most
neutralizing antibodies (Abs) elicited by influenza viruses target the head domain of the
hemagglutinin (HA) protein. Anti-HA head antibodies can be highly potent, but they have
limited breadth since the HA head is variable. There is great interest in developing new
universal immunization strategies that elicit broadly neutralizing antibodies against
conserved regions of HA, such as the stalk domain. Although HA stalk antibodies can
provide protection in animal models, it is unknown if they are present at sufficient levels in
humans to provide protection against naturally acquired influenza virus infections. Here,
we quantified H1N1 HA head- and stalk-specific antibodies in 179 adults hospitalized
during the 2015–2016 influenza virus season. We found that HA head antibodies, as
measured by hemagglutinin inhibition (HAI) assays, were associated with protection
against naturally acquired H1N1 infection. HA stalk-specific serum total IgG titers were
also associated with protection, but this association was attenuated and not statistically
significant after adjustment for HA head-specific antibody titers. We found slightly higher
titers of HA stalk-specific IgG1 and IgA antibodies in sera from uninfected participants than
in sera from infected participants; however, we found no difference in serum in
vitro antibody-dependent cellular cytotoxicity activity. In passive transfer experiments,
sera from participants with high HAI activity efficiently protected mice, while sera with low
HAI activity protected mice to a lower extent. Our data suggest that HA head antibodies
are more efficient at protecting against H1N1 infection than HA stalk Abs.
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Section 2.2 - Introduction
Seasonal influenza viruses cause annual epidemics worldwide. Although seasonal
influenza vaccines usually provide moderate protection against circulating strains, vaccine
effectiveness can be low when there are antigenic mismatches between vaccine strains
and circulating strains [295, 296]. Additionally, rare yet unpredictable influenza pandemics
occur when novel influenza virus strains cross the species barrier and transmit in the
human population [2].
Antibody-mediated immunity is important for protecting against influenza virus
infections [297]. The viral membrane protein, hemagglutinin (HA), is the target for most
anti-influenza virus neutralizing antibodies [133, 298-301]. Most neutralizing HA
antibodies target the HA globular head domain and block virus attachment to sialic acid,
the cellular receptor for influenza viruses. However, since the HA head is highly variable,
HA head antibodies generally exhibit poor cross-reactivity against antigenically drifted viral
strains [302]. Unlike the head domain, the stalk domain of HA is highly conserved between
different influenza virus strains. Antibodies that target the HA stalk domain can prevent
viral replication by inhibiting the pH-induced conformational changes of HA that are
required for viral entry into the cell [165]. Many HA stalk-specific antibodies also protect
by blocking HA maturation [165], inhibiting viral egress [164], or mediating Ab-dependent
cellular cytotoxicity (ADCC) [168]. Although HA stalk antibodies are typically subdominant
and are not thought to be as efficient as HA head Abs, HA stalk antibodies can inhibit
diverse influenza strains in vitro [148, 158, 284, 286].
Conventional influenza vaccines effectively elicit HA head-reactive antibodies but
not HA stalk antibodies [303]. As a result, influenza vaccine effectiveness is dependent on
the similarity of the HA head of circulating influenza virus strains and the HA head of
vaccine strains [304]. Antigenic mismatch between influenza vaccine strains and
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circulating viral strains have been especially problematic during recent years [223, 267].
To circumvent the potential for antigenic mismatch, as well as to prepare against new
pandemic viral strains, there is great interest in developing new universal immunization
strategies that elicit broadly reactive antibodies against conserved regions of HA, such as
the stalk domain [286, 305].
HA stalk antibodies protect animals from group 1 and group 2 influenza A virus
infections [158, 218, 285, 286, 306-310]. For example, human anti-HA stalk monoclonal
antibodies (mAbs) protect mice from lethal pH1N1 infection following prophylactic or
therapeutic passive transfers [218, 310] as well as against H5N1 [158, 306, 310] or H7N9
lethal dose challenge [309]. Both the prophylactic passive transfer of a human anti-HA
stalk mAb or the elicitation of HA stalk-specific antibodies by chimeric HA vaccination
decreases viral loads in ferrets following pH1N1 infection [307]. Additionally, passive
transfer of human sera from H5N1 vaccinees protects mice from lethal pH1N1 infection
[308], and this protection is likely mediated by HA stalk Abs. Passive transfer of broadly
neutralizing HA stalk-specific mAbs against group 2 influenza A viruses also protects mice
against heterosubtypic H3 viruses [285] and heterologous H3 and H7 viruses [286].
Vaccine strategies designed to elicit HA stalk antibodies in humans are currently being
pursued [273, 311, 312]. These strategies include sequential immunizations with chimeric
HAs [288, 304], immunization with headless HA antigens [159, 273, 275], and
immunizations with mRNA-based vaccines expressing HA [312].
Despite the recent interest in developing new HA stalk-based vaccines, the amount
of HA stalk antibodies required to protect humans from influenza virus infections and
influenza-related disease has not been established. A recent human pH1N1 challenge
study demonstrated that HA stalk antibody titers are associated with reduced viral
shedding but are not independently associated with protection against influenza infection
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[313]. While human influenza virus challenge studies are valuable, they have some
limitations. For example, high doses of virus are used in these studies [314, 315], large
numbers of individuals are typically prescreened for certain immunological attributes prior
to entering these studies [316], and the pathogenesis of infection differs from that of a
natural infection, including key sites of viral replication [315, 317]. Serological studies of
individuals who naturally acquire influenza virus infections can also be used to identify
specific types of antibodies that are associated with protection. Here, we present a
serological study to determine if serum HA head and stalk antibodies are associated with
protection against naturally acquired H1N1 infection.

Section 2.3 - Results
Assessment of HA head and stalk antibody association with protection against
H1N1 infection
We analyzed sera collected from 179 participants enrolled in a hospital-based
study during the 2015–2016 influenza season (Table 2.1). Adults hospitalized at the
University of Michigan Hospital (Ann Arbor, MI, USA) or Henry Ford Hospital (Detroit, MI,
USA) were enrolled according to a case definition of within ≤10 days of acute respiratory
illness onset and subsequently tested for influenza by reverse transcription-PCR (RTPCR). Serum specimens collected at hospital admission were obtained for estimation of
preinfection/early infection antibodies; 58% of specimens included in this analysis were
collected within 3 days of illness onset [318]. We analyzed serum samples from 62
hospitalized individuals that had PCR-confirmed H1N1 influenza virus infections. Serum
samples from 117 controls were selected from hospitalized individuals that had other
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respiratory diseases not caused by an influenza virus infection, matching by age category
(18 to 49 years, 50 to 64 years, and ≥65 years) and influenza vaccination status.
We quantified serum titers of HA head-specific antibodies against the predominant
2015–2016 H1N1 strain using hemagglutination inhibition (HAI) assays (Figure 2.1). HAI
assays detect HA head-specific antibodies that prevent influenza virus-mediated crosslinking of red blood cells [240, 241]. We found that HAI titers were associated with
protection against H1N1 infection in logistic regression models (Table 2.2). We observed
a 23.4% reduction in H1N1 infection risk with every 2-fold increase in HAI titer. Previous
studies reported that a 1:40 HAI titer is associated with 50% protection from experimental
human influenza infections [242]. Consistent with this, over 21% of non-H1N1-infected
cases possessed an HAI titer of >40, while only ∼3% of H1N1-infected cases possessed
an HAI titer of >40.

We next quantified relative titers of H1 stalk IgG antibodies using enzyme-linked
immunosorbent assays (ELISAs) coated with headless H1 proteins (Figure 2.1). Similar
to HAI titers, we found that H1 stalk titers were associated with protection against H1N1
infection in logistic regression models (Table 2.2). We observed a 14.2% reduction in
H1N1 infection risk with every 2-fold increase in H1 stalk titer. Whereas HAI titers of >40
were sharply associated with protection (Figure 2.1), there was no clear HA stalk IgG titer
cutoff that was associated with protection in our study (Figure 2.1)Samples with the
highest HA stalk IgG titers were interspersed among the uninfected and infected groups
(Figure 2.1)
Although both HAI titers and HA stalk IgG titers were associated with H1N1
protection in unadjusted models (Table 2.2), only HAI titers remained statistically
associated with protection in adjusted models (Table 2.2). HA stalk IgG-associated
protection lost significance when adjusting for HAI titers; however, the overall reduction in
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odds of infection for each 2-fold increase in titer remained roughly the same between the
unadjusted and adjusted models for both HAI (23.4% to 20.7%) and stalk antibody titers
(14.2% to 9.8%), respectively (Table 2.2).
We completed several experiments to validate our HA stalk IgG data. Headless
H1 proteins are engineered to possess only the HA stalk domain and not the HA globular
head domain [273]. We completed experiments with mAbs to verify that HA stalk-reactive
antibodies bind to headless H1 proteins in ELISAs. We found that the H1 head-specific
EM-4C04 mAb bound efficiently to a full-length H1 HA protein but failed to bind to our
headless H1 protein, while the H1 stalk-specific 70-1F02 mAb bound to each construct
similarly (Figure 2.2). We used two additional methods to verify that headless HA-based
ELISAs accurately quantify HA stalk-reactive Abs. First, we measured antibody binding to
a full-length HA chimeric protein that possessed an exotic head domain from an H6 virus
fused to the H1 stalk (abbreviated c6/H1) [319]. Since H6 viruses have never circulated in
the human population, most human antibodies that bind to this recombinant HA target the
HA stalk domain [304]. We found similar relative HA stalk antibody levels when we used
the c6/H1 HA-based ELISAs instead of headless HA-based ELISAs (Figure 2.2). We also
quantified HA stalk antibody levels using a competition ELISA. For these experiments, we
determined the amount of serum antibodies that was required to prevent the binding of a
biotinylated HA stalk-specific mAb (70-1F02). The 70-1F02 mAb recognizes a
conformationally dependent epitope that spans the HA1 and HA2 subunits [147, 148, 283,
284, 310]. We found that 70-1F02-based competition assay titers correlated strongly with
the headless HA-based ELISA titers (Figure 2.2).
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Assessment of HA stalk-specific serum antibody isotypes
Some HA stalk antibodies mediate protection through non-neutralizing
mechanisms that involve processes such as ADCC [167]. IgG1 and IgG3 antibody
subtypes are efficient at inducing ADCC, whereas IgG2 and IgG4 are not [320]. We
quantified relative IgG1, IgG2, and IgG3 HA stalk antibodies in serum from a subset of
participants using ELISAs coated with headless H1 proteins. In all participants, the
majority of HA stalk IgGs were IgG1 (Figure 2.3), consistent with previous reports [162,
321]. HA stalk IgG1 antibody titers were slightly higher in uninfected participants than in
infected participants (Figure 2.3). Total HA stalk IgG titers closely correlated with HA stalk
IgG1 titers (Figure 2.3). Undetectable levels of IgG2 and very low levels of IgG3 HA stalk
antibodies were detected in serum (Figure 2.3). We did not measure levels of IgG4 HA
stalk antibodies, since previous studies have shown that IgG4 is not prevalent among antiinfluenza virus human antibodies [162]. It is important to note that titers of each isotype
are directly comparable in our experiments, since we used control mAbs in each ELISA
(based on the CR9114 HA stalk mAb [322, 323]) that were engineered to possess the
same variable regions coupled to different constant regions.
We next evaluated serum HA stalk IgA Abs, since IgA antibodies can be important
for controlling respiratory infections. For example, mucosal IgA potently reduces the risk
of influenza transmission events in guinea pigs in a dose-dependent manner [324] and
suppresses the extracellular release of virus from infected cells [325]. Further, anti-HA
stalk mAbs engineered on an IgA backbone neutralize virus more effectively than when
they are engineered on an IgG backbone [326]. We did not have access to respiratory
secretions, but we did measure levels of HA stalk monomeric IgA in the serum from a
subset of participants. Similar to HA stalk IgG1 titers (Figure 2.3), we found that serum HA
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stalk IgA titers were slightly higher in uninfected participants than in infected participants
(Figure 2.3). IgG1 and IgA titers were moderately, though significantly, correlated (Figure
2.3).
Functionality of antibodies from infected and uninfected individuals
Antibodies against the HA head and HA stalk can neutralize or limit virus
replication through distinct mechanisms [147, 164, 165, 167, 168, 283, 286, 327, 328]. For
example, most antibodies that target epitopes near the receptor binding domain of the HA
head block virus binding and neutralize virus in vitro and in vivo [327]. Some HA stalk
antibodies can directly neutralize virus, but the majority of HA stalk antibodies require Fc
receptor engagement for protection in vivo [167, 284, 329]. Neutralizing HA stalk
antibodies typically inhibit HA conformational changes required to mediate fusion of the
virus and cellular membranes [147, 165, 283, 286]. Other HA stalk antibodies can prevent
subsequent viral expansion at later stages of infection by inhibiting HA maturation [165]
and viral egress [164].
We completed experiments to assess the in vitro and in vivo protective potential of
serum antibodies from a subset of infected and uninfected individuals. First, we
performed in vitro neutralization assays using green fluorescent protein (GFP)-reporter
influenza viruses [330]. We generated H1N1 viruses possessing genes encoding
enhanced GFP (eGFP) in place of most of the PB1 gene segment. The eGFP segment
retained the noncoding and 80 terminal coding nucleotides, allowing this segment to be
efficiently and stably packaged into virions. Neutralization assays were completed with
these viruses in cell lines that stably expressed PB1. We detected in vitro neutralization
titers in serum from approximately half of the participants that we tested. We found that in
vitro neutralization titers were significantly higher in the uninfected group than in the
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infected group by Welch’s t test (Figure 2.4). As expected, serum samples with the highest
HAI titers had high in vitro neutralization titers (Figure 2.4), whereas serum samples with
the highest HA stalk titers had more variable in vitro neutralization titers (Figure 2.4).
We next completed in vitro ADCC assays using serum from a subset of
participants. As controls, we also tested mAbs against the HA stalk (CR9114) and HA
head (EM-4C04). For these assays, we incubated HA-expressing 293T cells with serum
and then added human peripheral blood mononuclear cells (PBMCs). We then measured
CD107a (LAMP1) expression on CD3− CD56+ NK cells by flow cytometry. CD107a is a
sensitive NK cell degranulation marker whose expression levels strongly correlate with
cytokine production and cytotoxicity by NK cells in response to Ab-Fc receptor
engagement [331]. Consistent with previous studies [322], the CR9114 HA stalk mAb
activated NK cells more efficiently than the EM-4C04 HA head mAb (Figure 2.4). Serum
samples from participants also activated NK cells, but importantly, we found no differences
between NK activation in sera from infected and that from uninfected individuals (Figure
2.4).
Finally, we completed passive transfer experiments in mice. For these experiments
we passively transferred human sera into mice that have been engineered to possess
human Fc receptors [332] so that we could accurately assess the protective effects
mediated by human Fc-FcR interactions. We passively transferred pooled sera from
uninfected individuals that had high (>40) HAI titers (abbreviated as uninfected HAIhigh)
and uninfected individuals that had low (≤40) HAI titers (abbreviated as uninfected HAIlow).
We also passively transferred pooled sera from infected individuals, all of whom had low
(≤40) HAI titers (abbreviated as infected HAIlow). For these experiments, equal volumes of
human sera were transferred for each experimental condition. Mice were challenged with
a sublethal dose of H1N1 4 hours after serum transfer, and body weights were monitored
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for 15 days (Figure 2.5). Mice that received sera from uninfected HAIhigh participants were
fully protected against H1N1 infection. Mice that received sera from HAIlow participants,
whether from uninfected or infected individuals, were moderately protected against H1N1
infection, although these sera conferred significantly less protection than sera from
HAIhigh participants (Figure 2.5 and Table 2.3).
Since there were different amounts of HA antibodies in sera from uninfected HAIhigh
participants, uninfected HAIlow participants, and infected participants (Figure 2.5), it is
unclear if the differences in our passive transfer experiments were due to differences in
overall HA antibody titers or differences in HA head and stalk antibody ratios. To address
this, we repeated passive transfer experiments after adjusting serum amounts so that
equal amounts of HA antibodies were passively transferred in each experimental group.
Similar to what we found in our initial passive transfer experiment, sera from uninfected
HAIhigh participants protected mice better than sera from uninfected HAIlow participants and
infected participants (Figure 2.5 and Table 2.4). Interestingly, sera from uninfected
HAIlow participants protected mice better than sera from infected participants after
adjusting serum amounts based on HA antibody titers (Figure 2.5 and Table 2.4). Taken
together, these data suggest that human sera with high HAI activity efficiently protect in
vivo, while human sera with low HAI activity also protect in vivo, albeit to a lower extent.

Section 2.4 - Discussion
Observational studies can be useful in identifying antibody types that are
associated with protection from influenza virus infection. Here, we found that both HA head
and stalk antibodies appeared to be associated with preventing H1N1 hospitalizations
during the 2015–2016 season. We found that the effect size of HAI-associated protection
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(23.4% reduced risk of infection for every 2-fold increase in titer) was larger than the effect
size of HA stalk Ab-associated protection (14.2% reduced risk of infection for every 2-fold
increase in titer). In our study, HAI titers were independently associated with protection in
adjusted models; however, HA stalk antibodies were not. However, the effects of both HAI
and HA stalk antibody titers were only slightly attenuated in our adjusted model, and it is
possible that our relatively small sample size limited our ability to detect an independent
association between HA stalk titers and protection.
There are several limitations to our study. Since our sample size was relatively
small, we only evaluated the contribution of antibodies to the HA head and stalk. Larger
studies will be required to independently evaluate other immune correlates of protection.
For example, it will be important for future studies to evaluate the relationship between HA
head and stalk antibody-associated protection and neuraminidase (NA) Ab-associated
protection. Recent studies have shown that NA antibodies are associated with protection
in an H1N1 challenge cohort [313], and NA antibodies were also identified as an
independent correlate of protection in a controlled vaccine efficacy study [143]. It will be
critical to determine if NA Ab-associated protection is independent of the protective effects
of HA head and stalk Abs.
It should be noted that participants in our study were likely admitted to the hospital
at various days post-infection. While most blood specimens were collected relatively early
(≤3 days after symptom onset), we cannot exclude that some participants in our studies
were infected for a prolonged period of time before being admitted to the hospital. This
raises the possibility that some participants have already mounted de novo antibody
responses to H1N1 infection, which could convolute the analyses of antibody types
associated with protection. While this is a possibility, it is less of a concern since we found
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that all infected individuals have very low HAI titers. If our infected participants were
making de novo antibody responses, we would anticipate that some of them would have
high HAI titers to the infecting H1N1 virus. In addition, antibody titers do not typically
increase as days from symptom onset to blood specimen collection increases [318], which
suggests that samples used in this study were collected prior to the generation of de
novo antibody responses against the infecting virus.
It is interesting that in vitro neutralization titers (Figure 2.4), but not ADCC titers
(Figure 2.4), were associated with H1N1 protection. In vitro neutralization activity is mainly
driven by HA head antibodies [133, 298-301], whereas HA stalk antibodies are more
effective at ADCC [167]. It should be noted that HA stalk IgG1 and IgA antibodies have
been shown to mediate phagocytosis with innate cellular partners [173], which could prove
to be an important mechanism of protection by HA stalk antibodies and should be
considered in future studies. HA head antibodies were associated with greater protection
in our cohorts than stalk antibodies (Table 2.4), and these antibodies conferred protection
superior to that of HA stalk antibodies when passively transferred into mice (Figure 2.4).
Interestingly, serum from HAIlow uninfected participants protected mice better than serum
from HAIlow infected participants in passive transfer studies after normalizing total HA
antibody amounts under each transfer condition. While these data suggest that HA stalk
antibodies can confer protection in vivo, we cannot rule out that other immune components
(such as NA Abs) contributed to protection in these experiments.
Taken together, our findings provide important new insights into the prevalence
and functionality of HA head and stalk antibodies in humans. Future studies that tease out
the interdependence of HA head and stalk antibodies, as well as antibodies and T cells
against other viral antigens, will be useful in guiding the development of new universal
influenza vaccine antigens.
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Section 2.5 - Materials and Methods
Human subjects: During the 2015–2016 influenza season, adult (≥18 years) patients
hospitalized for treatment of acute respiratory illnesses at the University of Michigan
Hospital in Ann Arbor, MI, and Henry Ford Hospital in Detroit, MI, were prospectively
enrolled in a case test-negative design study of influenza vaccine effectiveness. All
participants provided informed consent and were enrolled ≤10 days from illness onset
during the period of influenza circulation (January to April of 2015 and 2016). Participants
completed an enrollment interview and had throat and nasal swab specimens collected
and combined for influenza virus identification. Influenza vaccination status was defined
by self-report and documentation in the electronic medical record and Michigan Care
Improvement Registry (MCIR). When available, clinical serum specimens collected as
early as possible after hospital admission were retrieved; all specimens were collected
≤10 days from illness onset based on the enrollment case definition. Studies involving
humans were approved by the Institutional Review Boards of the University of Michigan
and University of Pennsylvania. All experiments (HAI, ELISAs, in vitro neutralization
assays, ADCC assays, and passive transfers) were completed at the University of
Pennsylvania using deidentified sera.
Viruses: Viruses possessing A/California/07/2009 HA and NA or A/HUP/04/2016 HA and
NA were generated by reverse genetics using internal genes from A/Puerto Rico/08/1934.
Viruses were engineered to possess the Q226R HA mutation, which facilitates viral growth
in chicken eggs. Viruses were grown in fertilized chicken eggs, and the HA gene was
sequenced to verify that additional mutations did not arise during propagation. We isolated
the A/HUP/04/2016 virus from respiratory secretions obtained from a patient at the
Hospital of the University of Pennsylvania in 2016. For this process, deidentified clinical
material from the Hospital of the University of Pennsylvania Clinical Virology Laboratory
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was added to Madin-Darby canine kidney (MDCK) cells (originally obtained from the
National Institutes of Health) in serum-free medium with l-(tosylamido-2-phenyl) ethyl
chloromethyl ketone (TPCK)-treated trypsin, HEPES, and gentamicin. Virus was isolated
from the infected MDCK cells 3 days later. We extracted viral RNA and sequenced the HA
gene of A/HUP/04/16.
Recombinant HA proteins: Plasmids encoding the recombinant headless HA stalk were
provided by Adrian McDermott and Barney Graham from the Vaccine Research Center at
the National Institutes of Health. The headless HA stalk protein was expressed in 293F
cells and purified using nickel-nitrilotriacetic acid agarose (no. 1018244; Qiagen) in 5-ml
polypropylene columns (no. 34964; Qiagen), washed with pH 8 buffer containing 50 mM
Na2HCO3, 300 mM NaCl, and 20 mM imidazole, and then eluted using pH 8 buffer
containing 50 mM Na2HCO3, 300 mM NaCl, and 300 mM imidazole. Purified protein was
buffer exchanged into phosphate-buffered saline (PBS; no. 21-031-CM; Corning).
Following purification, the headless HA stalk proteins were biotinylated using the Avidity
BirA-500 kit (no. BirA500) and stored in aliquots at −80°C. Plasmids encoding the
recombinant chimeric (c6/H1) HA were provided by Florian Krammer (Mt. Sinai). The
detailed protocol for expression of this protein is published elsewhere [319]. In brief, the
c6/H1 HA protein was expressed in High Five baculovirus cells and purified using the
same methods referenced for the headless HA stalk protein. Purified protein was buffer
exchanged into PBS (no. 21-031-CM; Corning) and stored in aliquots at −80°C.
MAbs: Plasmids encoding the human mAb EM-4C04, 70-1F02, and CR9114 IgG1
isotypes were provided by Patrick Wilson at the University of Chicago. The heavy-chain
constant regions for IgG2, IgG3, and IgA (sequences listed below) were synthesized as a
gBlock by IDT and cloned into the pSport6 vector containing the heavy chain of CR9114.
All mAbs were expressed in 293T cells and purified 4 days postinfection using NAb protein
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A/G spin kits (no. 89950; Thermo Fisher) for the IgG isotypes or using peptide M agarose
(no. gel-pdm-2; InvivoGen) for the IgA isotype.
The IgG2 sequence is:
CGCATGATGCGTCGACCAAGGGTCCTAGCGTTTTCCCGCTCGCACCTTGTAGTCG
GAGCACCTCCGAATCTACGGCGGCGCTCGGATGTCTGGTTAAGGATTACTTTCCTG
AACCTGTTACTGTATCTTGGAATTCAGGAGCACTGACATCTGGTGTACATACTTTTC
CAGCGGTTTTGCAGTCATCTGGTCTTTATTCCCTGTCCAGTGTGGTAACAGTACCAT
CCTCAAACTTTGGAACTCAGACCTATACCTGCAATGTGGACCACAAGCCATCCAATA
CAAAAGTCGATAAGACTGTCGAGCGGAAGTGCTGTGTCGAATGCCCTCCCTGCCC
CGCTCCGCCGGTTGCAGGGCCAAGTGTATTTCTTTTTCCACCAAAACCAAAAGATA
CGCTTATGATATCTCGCACGCCTGAAGTAACCTGCGTAGTCGTTGATGTAAGTCAC
GAGGATCCCGAAGTTCAATTCAATTGGTATGTAGATGGCGTTGAAGTGCATAATGC
AAAGACCAAACCTAGAGAAGAACAATTCAATAGTACCTTTCGCGTGGTTAGCGTACT
CACAGTCGTCCACCAGGATTGGCTGAATGGGAAGGAGTACAAATGCAAGGTCTCTA
ACAAAGGTCTTCCGGCCCCCATAGAAAAAACGATCAGTAAGACCAAGGGGCAGCC
CAGAGAGCCACAGGTTTATACGTTGCCTCCGTCTCGCGAGGAAATGACTAAAAACC
AGGTCAGCCTGACTTGTTTGGTGAAAGGGTTTTACCCGAGCGATATTGCTGTGGAA
TGGGAGAGTAACGGGCAACCGGAGAACAATTACAAAACGACACCGCCCATGCTTG
ATAGTGATGGTTCCTTCTTCTTGTACAGCAAGTTGACGGTTGATAAATCCAGGTGGC
AGCAAGGAAATGTTTTCTCTTGTTCAGTGATGCATGAGGCGCTCCACAACCATTATA
CGCAAAAATCACTCTCACTTTCACCGGGGAAATGAAGCTTGAGCAGGGCCT.
The IgG3 sequence is:
CGCATGATGCGTCGACCAAAGGGCCGTCAGTCTTTCCCTTGGCGCCGTGCTCCAG
GAGTACCAGCGGCGGCACCGCGGCGTTGGGATGTCTTGTCAAGGATTATTTTCCC
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GAACCCGTCACCGTAAGCTGGAACAGTGGGGCATTGACGTCTGGCGTTCATACTTT
TCCGGCAGTACTTCAGAGTTCCGGCCTTTATTCTTTGTCAAGCGTTGTTACCGTACC
ATCCAGTAGCCTTGGCACCCAGACCTACACCTGTAATGTTAATCACAAACCAAGTAA
CACCAAGGTTGATAAGAGGGTTGAGCTTAAAACACCGCTTGGTGACACAACCCATA
CGTGTCCAAGATGTCCGGAGCCGAAGAGTTGTGATACCCCGCCGCCGTGTCCTCG
CTGTCCGGAACCAAAGAGCTGTGATACCCCCCCACCTTGTCCCAGATGTCCTGAAC
CGAAATCATGTGACACGCCACCACCTTGCCCAAGATGTCCCGCGCCAGAGCTGCT
GGGTGGGCCCAGCGTATTTCTTTTTCCACCCAAACCGAAGGATACCCTTATGATAA
GCAGGACTCCCGAGGTTACCTGCGTGGTGGTTGACGTAAGTCACGAAGACCCCGA
AGTCCAATTCAAATGGTATGTTGATGGGGTCGAAGTACACAACGCGAAGACTAAAC
CGAGAGAGGAACAGTATAATAGCACATTCCGGGTTGTTTCCGTACTTACAGTACTTC
ATCAGGACTGGCTTAATGGCAAGGAGTACAAGTGCAAAGTCAGTAACAAGGCACTC
CCTGCTCCGATTGAAAAGACAATATCAAAGACGAAAGGTCAACCCAGAGAGCCGCA
GGTCTACACACTCCCTCCGTCCAGAGAAGAGATGACGAAAAACCAAGTTTCATTGA
CGTGCCTCGTTAAAGGATTCTACCCAAGCGACATAGCTGTTGAGTGGGAGAGCAG
CGGCCAGCCTGAGAACAATTATAATACTACCCCCCCCATGCTCGACTCTGATGGTA
GTTTTTTTCTGTACTCCAAGCTGACGGTAGACAAAAGTAGATGGCAGCAAGGCAAC
ATCTTCAGTTGCTCTGTTATGCACGAGGCGTTGCACAACCGATTCACACAGAAGTC
ACTGAGCCTGTCTCCGGGTAAATGAAGCTTGAGCAGGGCCT.
The IgA sequence is:
CGCATGATGCGTCGACTTCTCCAAAAGTGTTTCCCCTCAGTTTGTGTTCCACTCAAC
CGGATGGTAACGTGGTGATTGCTTGTCTCGTGCAAGGTTTTTTCCCACAGGAACCG
CTGAGTGTTACATGGTCAGAGTCAGGCCAAGGTGTAACCGCGCGCAACTTTCCCC
CTTCACAGGACGCTAGTGGCGATCTGTATACTACCTCCTCTCAGCTCACTCTTCCC
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GCCACACAATGCCTCGCTGGGAAATCTGTAACCTGCCACGTTAAACATTACACTAAT
CCATCACAGGACGTTACCGTGCCGTGCCCTGTACCATCCACGCCGCCTACGCCGT
CACCGTCAACTCCTCCTACTCCCTCACCCTCTTGTTGTCACCCGCGCCTCTCTCTTC
ACAGACCGGCCTTGGAGGACCTTCTCCTTGGGTCTGAGGCGAATTTGACTTGCAC
GCTCACGGGGTTGCGGGACGCTAGTGGGGTTACGTTTACATGGACACCTTCATCA
GGGAAGTCTGCCGTTCAGGGCCCCCCAGAGCGCGATTTGTGCGGGTGTTACAGCG
TATCTTCTGTGCTGCCTGGGTGCGCTGAGCCCTGGAATCACGGCAAAACGTTTACC
TGCACCGCTGCTTACCCAGAGAGCAAAACCCCTCTGACGGCTACATTGTCCAAGTC
AGGCAACACATTTCGCCCCGAAGTCCACCTCTTGCCACCTCCATCCGAAGAACTCG
CCCTGAACGAACTCGTGACGCTGACGTGCCTTGCACGCGGCTTTTCCCCGAAAGA
CGTTCTCGTCCGGTGGCTTCAAGGTTCTCAGGAACTCCCACGGGAGAAGTACCTG
ACCTGGGCTTCACGCCAGGAACCTTCACAAGGGACGACCACTTTCGCAGTCACGT
CAATTCTGAGAGTTGCCGCTGAGGACTGGAAGAAGGGAGATACTTTCAGTTGTATG
GTAGGTCACGAAGCACTGCCGCTGGCATTTACGCAGAAAACCATCGATCGGCTTG
CCGGAAAGCCTACTCATGTTAACGTTTCCGTAGTGATGGCGGAGGTAGATGGCACA
TGTTACTGAAGCTTGAGCAGGGCCT.
HAI assays: Serum samples were pretreated with receptor-destroying enzyme (no.
370013; Denka Seiken) followed by hemadsorption, in accordance with WHO
recommended protocols [333]. HAI titrations were performed in 96-well U-bottom plates
(no. 353077; Corning). Sera were initially diluted 2-fold and then added to four
agglutinating doses of virus, for a final volume of 100 μl/well. Turkey erythrocytes (no.
7209401; Lampire) were added to each well (12.5 μl diluted to 2%, vol/vol). The
erythrocytes were gently mixed with sera and virus and then allowed to incubate for 1 h at
room temperature. Agglutination was read and HAI titers were expressed as the inverse
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of the highest dilution that inhibited four agglutinating doses of virus. Each HAI assay was
performed independently on two different days.
Headless HA ELISAs: Headless HA ELISAs were performed on 96-well Immulon 4HBX
flat-bottom microtiter plates (no. 3855; Thermo Fisher) coated with 0.5 μg/well of
streptavidin (no. S4762; Sigma). We completed total IgG headless HA ELISAs with all
serum samples and isotype headless HA ELISAs with serum samples that had sufficient
volumes. Biotinylated headless HA protein was diluted in biotinylation buffer containing 1×
Tris-buffered saline (TBS; no. 170-6435; Bio Rad), 0.005% Tween (no. 170-6531; Bio
Rad), and 0.1% bovine serum albumin (no. A8022; Sigma) to 0.25 μg/ml, and 50 μl was
added per well and incubated on a rocker for 1 h at room temperature. Each well was then
blocked for an additional 1 h at room temperature using biotinylation blocking buffer
containing 1× TBS (no. 170-6435; Bio Rad), 0.005% Tween 20 (no. 170-6531; Bio Rad),
and 1% bovine serum albumin (no. A8022; Sigma). Each serum sample was serially
diluted in biotinylation buffer (starting at 1:100 dilution for total IgG or 1:50 dilution for
antibody isotype), added to the ELISA plates, and allowed to incubate for 1 h at room
temperature on a rocker. As a control, we added the human CR9114 stalk-specific mAb,
starting at 0.03 μg/ml, to verify equal coating of plates and to determine relative serum
titers. Peroxidase-conjugated goat anti-human IgG (no. 109-036-098; Jackson),
peroxidase-conjugated mouse anti-human IgG1 (no. 9054-05; Southern Biotech),
peroxidase-conjugated mouse anti-human IgG2 (no. 9060-05; Southern Biotech),
peroxidase-conjugated mouse anti-human IgG3 (no. 9210-05; Southern Biotech), or
peroxidase-conjugated goat anti-human IgA (no. 2050-05; Southern Biotech) was
incubated for 1 h at room temperature on a rocker. Finally, SureBlue TMB peroxidase
substrate (no. 5120-0077; KPL) was added to each well, and the reaction was stopped
with the addition of 250 mM HCl solution. Plates were extensively washed with PBS (no.
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21-031-CM; Corning) and 0.1% Tween 20 (no. 170-6531; Bio Rad) between each step
using a BioTek 405 LS microplate washer. Relative titers were determined using a
consistent concentration of the CR9114 mAb for each plate and reported as the
corresponding inverse of the serum dilution that generated the equivalent optical densities
(OD). Each type of ELISA (total IgG, IgG1, IgG2, IgG3, and IgA) was performed twice.
Chimeric (c6/H1) HA ELISAs: Chimeric HA ELISAs were performed on 96-well Immulon
4HBX flat-bottom microtiter plates (no. 3855; Thermo Fisher). HA proteins were diluted in
PBS (no. 21-031-CM; Corning) to 2 μg/ml and coated at 50 μl per well overnight at 4°C.
Plates were blocked using an ELISA buffer containing 3% goat serum (no. 16210-064;
Gibco), 0.5% milk (no. DSM17200-1000; Dot Scientific, Inc.), and 0.1% Tween 20 (no.
170-6531; Bio Rad) in PBS (no. 21-031-CM; Corning) 1× for 2 h at room temperature.
Each serum sample was serially diluted in the ELISA buffer (starting at 1:100 dilutions),
added to the ELISA plates, and allowed to incubate for 2 h at room temperature. As a
control, we added the human CR9114 stalk-specific mAb, starting at 0.03 μg/ml, to verify
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat
anti-human IgG (no. 109-036-098; Jackson) next was incubated for 1 h at room
temperature. Finally, SureBlue TMB peroxidase substrate (no. 5120-0077; KPL) was
added to each well, and the reaction was stopped with the addition of 250 mM HCl
solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1%
Tween 20 (no. 170-6531; Bio Rad) between each step using a BioTek 405 LS microplate
washer. Relative titers were determined using a consistent concentration of the CR9114
mAb for each plate and reported as the corresponding inverse of the serum dilution that
generated the equivalent OD. Each ELISA was performed twice.
Competition ELISAs: Competition ELISAs were performed on 96-well Immulon 4HBX
flat-bottom microtiter plates (no. 3855; Thermo Fisher). HA proteins were diluted in 1×
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Dulbecco’s PBS (DPBS; no. 21-031-CM; Corning) to 2 μg/ml and coated at 50 μl per well
overnight at 4°C. Plates were blocked using the biotinylation blocking buffer, described
earlier, for 2 h at room temperature. Each serum sample was serially diluted in biotinylation
buffer (starting at 1:10 dilution), added to the ELISA plates, and allowed to incubate for 1
h at room temperature before adding human 70-1F02 mAb (specific for the
conformationally dependent HA stalk epitope 1 [334]) that had been biotinylated using the
Invitrogen SiteClick biotin antibody labeling kit (no. S20033; Thermo Fisher) at a constant
concentration of 0.03 μg/ml and incubated at room temperature for an additional hour. As
a control, we added the human CR9114 stalk-specific mAb, starting at 0.03 μg/ml, to verify
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated
streptavidin (no. 554066; BD Pharmingen) next was incubated for 1 h at room
temperature. Finally, SureBlue TMB peroxidase substrate (no. 5120-0077; KPL) was
added to each well, and the reaction was stopped with the addition of 250 mM HCl
solution. Plates were extensively washed with PBS (no. 21-031-CM; Corning) and 0.1%
Tween 20 (no. 170-6531; Bio Rad) between each step, with the exception of the addition
of biotinylated 70-1F02, using a BioTek 405 LS microplate washer. Relative titers were
determined using the uncompeted control lane OD (biotinylated 70-1F02 binding in the
absence of sera) and setting that OD to 100%. Each serum sample was then assessed
by nonlinear regression using GraphPad Prism. Titers are reported as the inverse of the
highest serum dilution that inhibited binding of the biotinylated 70-1F02 to 30% of the
uncompeted binding. Each competition ELISA was performed independently on two
different days.
In vitro neutralization assays: In vitro neutralization assays were completed using a
subset of samples. We excluded samples that had limited amounts of sera. Plasmids
encoding pH1N1 viruses possessing genes encoding eGFP in place of most of the PB1
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gene segment were provided by Jesse Bloom at The Fred Hutchinson Cancer Research
Center. The eGFP segment retained the noncoding and 80 terminal coding nucleotides,
allowing this segment to be efficiently and stably packaged into the virions. Detailed
protocols for the reverse genetics, expression, and in vitro neutralization assays using the
recombinant viruses have been published elsewhere [330, 335]. In brief, serum was
pretreated with receptor-destroying enzyme (no. 370013; Denka Seiken) and then serially
diluted in neutralization assay medium (Medium 199; no. 11150-059; Gibco)
supplemented with 0.01% heat-inactivated fetal bovine serum (FBS; no. F0926-100;
Sigma), 0.3% bovine serum albumin (no. A8022; Sigma), 100 U penicillin–100 μg
streptomycin/ml (no. 30-002-Cl; Corning), 100 μg of calcium chloride/ml (no. S7653;
Sigma), and 25 mM HEPES (no. 25-060-Cl; Corning), beginning at a 1:80 dilution.
PB1flank-eGFP viruses were then added to the serum dilutions and were incubated at
37°C for 1 h to allow for neutralization. As a control, the human CR9114 HA stalk-specific
mAb was added to ensure equal infectivity and neutralization across all plates. Viruses
and sera then were transferred to 96-well flat-bottom tissue culture plates containing
80,000 cells per well of MDCK-SIAT1-TMPRSS2 cells constitutively expressing PB1 under
a cytomegalovirus promoter. Plates were incubated at 37°C for 30 h postinfection. Mean
fluorescent intensity of samples was read using an Envision plate reader (monochromator,
top read, excitation filter at 485 nm, emission filter at 530 nm). Neutralization titers were
reported as the inverse of the highest dilution that decreased mean fluorescence by 90%
relative to infected control wells in the absence of antibodies. Each neutralization assay
was performed independently on two different days.
ADCC activity assays: ADCC activity assays were completed using a subset of samples.
We excluded samples that had limited amounts of sera. 293T cells were plated at 3.5e4
cells per well in a 96-well flat-bottom tissue culture plate (no. 353072; Corning) 24 h before
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transfection. 293T cells were then transfected using 20 μl Opti-MEM (no. 31985-070;
Gibco), 1 μl Lipofectamine 2000 (no. 11668-019; Invitrogen), and 500 ng plasmids
encoding the HA gene from A/California/07/09 per well and incubated at 37°C for
approximately 30 h before performing the ADCC assay. Approximately 12 h before
performing the ADCC assay, frozen PBMCs from four separate donors (obtained through
the University of Pennsylvania Human Immunology Core) were thawed at 37°C and then
washed 3× using 15 ml of warmed complete RPMI medium (no. 10-040-CM; Corning)
(supplemented with 10% heat-inactivated FBS [no. F0926-100; Sigma], 1% penicillinstreptomycin [no. 30-002-Cl; Corning]). Each aliquot of PBMCs was then transferred to a
50-ml conical tube and rested overnight in 23 ml of complete RPMI medium at a 5° angle,
with the cap loosened to allow for gas exchange. On the day of the assay, serum samples
were diluted in Dulbecco’s modified Eagle’s medium (no. 10-013-CM; Corning)
supplemented with 10% FBS (no. F0926-100; Sigma) at a 1:10 dilution. As a control for
this assay, the human CR9114 HA stalk-specific mAb was included at a concentration of
5 μg/ml to ensure efficient activation of ADCC. Transfected 293T cells were loosened by
pipetting and transferred to a 96-well U-bottom plate (no. 353077; Corning) and spun down
for 1 min at 1,200 rpm, and the medium was flicked out. The serum/mAb dilutions were
transferred to the plates containing the transfected 293T cells and were mixed with the
transfected cells by gentle pipetting and incubated at 37°C for 2 h. PBMC aliquots were
combined, spun down, and counted, and a master mix of 2e7 cells/ml was set up using
complete RPMI medium. Aliquots of the PBMC master mix were set up for the live/dead
and unstained control wells. Phycoerythrin-conjugated mouse anti-human CD107a (no.
328608; BioLegend) was added at a 1:50 dilution. Brefeldin A (no. B7651; Sigma) was
added to 10 μg/ml. Monensin (no. 51-2092KZ; BD BioSciences) was added to 5 μl per 1 ml
of PBMC master mix concentration. An aliquot of 200 μl was made, phorbol myristate
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acetate (no. P1585; Sigma) was added to a 5 μg/ml concentration, and ionomycin (no.
I9657; Sigma) was added to a 1 μg/ml concentration. Serum/cell suspensions were spun
down at 1,200 rpm for 1 min, and medium was flicked out. The PBMC master mix and the
aliquots for the various controls were plated at 50 μl per well and mixed gently by pipetting,
followed by incubation at 37°C for 4 h. Cells were then stained in the following manner.
Live/dead fixable near-infrared stain (no. L34976; Thermo) was diluted 1:50 in DPBS (no.
21-031-CM; Corning) and 1% bovine serum albumin (no. A8022; Sigma) for 30 min in the
dark at 4°C. Human FcR blocking reagent (no. 130-059-901; Miltenyi Biotec) was diluted
1:25 in DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022;
Sigma) and incubated in the dark for 10 min at 4°C. Alexa Fluor 647-conjugated mouse
anti-human-CD3 (no. 344826; BioLegend) and BV421-conjugated mouse anti-human
CD56 (no. 318328; BioLegend) were diluted 1:200 in DPBS (no. 21-031-CM; Corning)
plus 1% bovine serum albumin (no. A8022; Sigma) and incubated in the dark for 30 min
at room temperature. Cells were then fixed using 10% paraformaldehyde (no. 15714-S;
Electron Microscopy Sciences) diluted in MilliQ water for 6 min at room temperature. Cells
were extensively washed with DPBS (no. 21-031-CM; Corning) and 1% bovine serum
albumin (no. A8022; Sigma) between each step. Cells were stored overnight at 4°C in
100 μl/well of DPBS (no. 21-031-CM; Corning) and 1% bovine serum albumin (no. A8022;
Sigma). Flow cytometry was performed using and LSRII (BD Biosciences, San Diego,
CA). Compensation controls were set up using anti-mouse Igκ beads (no. 552843; BD
BioSciences) and run for each antibody for every experiment, and voltages were adjusted
accordingly. All data were analyzed in FlowJo (Ashland, OR) by gating on single cells that
were CD3− CD56+ CD107a+in control wells that did not contain serum/mAb to adjust for
basal levels of CD107a expression. These gates were then applied to each serum sample,
and ADCC activity was expressed as a percentage of NK cells expressing CD107a+. Each
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ADCC assay was performed independently on three different days, and the same four
PBMC donors were pooled and used for each replicate.
Murine experiments: All mouse experiments were reviewed and approved by the
IACUCs of the Wistar Institute and University of Pennsylvania. All passive transfer
experiments were performed in humanized FcR mice (hFcgR [1, 2a, 2 b, 3a, 3b]tg+/mFcgR
alpha chain [1, 2 b, 3, 4]−/−) that were provided by Jeffrey Ravetch at the Rockefeller
University [332]. Sera were pooled into three groups, uninfected HAIhigh(>40 HAI titer),
uninfected HAIlow (≤40 HAI titer), and infected HAIlow (≤40 HAI titer), and then heat treated
for 30 min at 55°C. Serum or sterile PBS was then transferred into mice by intraperitoneal
injection. Four hours posttransfer, mice were bled by submandibular puncture,
anesthetized using isoflurane, and challenged intranasally using 50 μl of sterile PBS
containing a sublethal dose (9e4 50% tissue culture infective dose units) of
A/California/07/09. ELISAs were run on the sera collected from each animal to verify that
the passive transfer was successful. Mice were weighed on the day on infection and then
daily for 15 days postinfection. Weight loss was reported as percent weight loss relative
to the starting weight of each mouse. For the passive transfer normalized by volume, two
independent experiments were performed using a mix of male and female humanized FcR
mice for a total of 6 mice per group per experiment. For the passive transfer normalized
by HA antibody titer, a single experiment was performed using a mix of male and female
humanized FcR mice for a total of 6 mice per group, since we had limited amounts of sera
available for this study. One-way analysis of variance (ANOVA) was performed for each
day postinfection between groups using GraphPad Prism software.
Statistical analysis: Fisher’s exact tests, one-way ANOVAs, and Welch’s t tests were
completed using GraphPad software. Both unadjusted and adjusted logistic regression
analyses were performed using R Studio (version 1.0.153)
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Figure 2.1

Figure 2.1. Assessment of HA head and stalk antibody association with protection.
(A) HAI assays were completed using sera from uninfected (gray) and infected (red)
individuals. HAI titers are associated with protection against H1N1 infection (P = 0.0108,
logistic regression of log2 geometric mean titers from two independent experiments). (B)
ELISAs using headless HA constructs were completed using sera from uninfected (gray)
and infected (red) individuals. HA stalk-specific antibodies are associated with protection
against influenza infection (P = 0.0417, logistic regression analysis using log2 geometric
mean titers from two independent experiments). (C) HA head antibodies measured by HAI
and HA stalk titers measured by ELISA using headless HA stalk constructs are weakly,
though significantly, correlated (r = 0.2778, P = 0.0002, Spearman correlation using
log2 geometric mean titers from two independent experiments for each measurement). In
all panels, each circle represents a serum sample from a single individual.
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Figure 2.2

Figure 2.2. Validation of headless H1 HA stalk construct. We completed additional
ELISAs using the 70-1F02 HA stalk mAb and the EM-4C04 HA head mAb and plates
coated with headless HA (A) or full-length HA (B). Graphs depict representative results
from two independent experiments. (C) We quantified HA stalk antibodies using ELISA
plates coated with c6/H1 proteins. HA stalk titers measured by ELISA using c6/H1 or
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headless HA stalk constructs were tightly correlated (r = 0.7776, P < 0.0001, Spearman
correlation using log2 geometric mean titers from two independent experiments). (D) We
completed competition assays using the conformationally dependent 70-1F02 mAb. 701F02 competition titers are tightly correlated with overall HA stalk antibody titers in both
infected and uninfected individuals (r = 0.9097, P < 0.0001, Spearman correlation using
log2geometric mean titers from two independent experiments). In panels C and D, each
circle represents a serum sample from a single individual.
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Figure 2.3

Figure 2.3. Assessment of HA stalk-specific serum antibody isotypes. (A) ELISAs
were completed to quantify the levels of IgG1, IgG2, IgG3, and IgA HA stalk antibodies in
each serum sample. Higher titers of HA stalk-specific IgG1 and IgA were present in
uninfected individuals but not in infected individuals (P = 0.0180 and P = 0.0426,
respectively, by Welch’s t test using log2-transformed mean titers from two independent
experiments). (B) IgG1 HA stalk antibody titers closely correlated with total IgG HA stalk

60

antibody titers (r = 0.9184, P < 0.0001, Spearman correlation using log2 geometric mean
titers from two independent experiments). (C) IgA HA stalk antibody titers moderately
correlated with IgG1 HA stalk antibody titers (r = 0.3500, P < 0.0001, Spearman correlation
using log2geometric mean titers from two independent experiments). In all panels, each
circle represents a serum sample from a single individual.
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Figure 2.4

Figure 2.4. In vitro functionality of HA antibodies from infected and uninfected
individuals. (A) In vitro neutralization assays were completed with sera from uninfected
and infected individuals. In vitro neutralization titers are significantly higher in uninfected
than infected participants (P = 0.0026, Welch’s t test using log2mean titers from two
independent experiments). Neut90, neutralization titer at which the inverse of the highest

62

dilution decreased mean fluorescence by 90% relative to infected control wells in the
absence of antibodies. (B) HAI titers correlate strongly with neutralization titers
(r = 0.5073, P < 0.0001, Spearman correlation using log2 geometric mean titers from two
independent experiments). (C) HA stalk titers also correlate with neutralization titers
(r = 0.4574, P < 0.0001, Spearman correlation using log2 geometric mean titers from two
independent experiments). (D) ADCC assays were completed using sera from uninfected
and infected individuals. Assays were also completed using the CR9114 and EM-4C04
mAbs. As negative controls, we completed ADCC assays using 293T cells without HA or
293T cells with HA but without Ab. ADCC activity is not significantly different between the
uninfected and infected participants (P = 0.9538, Welch’s t test using log2 mean titers from
three independent experiments).
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Figure 2.5

Figure 2.5. HA head and stalk antibodies confer protection from severe disease in
vivo. (A) Passive transfer experiment design and timeline. Sera were stratified by HAI titer
and infection status, pooled, and transferred intraperitoneally to humanized Fc-receptor
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mice 4 h before challenge with A/California/07/2009. Weights were measured daily for
15 days. (B) We transferred equal volumes of sera into each mouse for our initial
experiments. Mice that received uninfected HAIhigh sera were completely protected against
infection (gray line). Mice that received HAIlow sera (uninfected or infected, blue and red
lines, respectively) were also protected but were significantly less protected than the mice
that received HAIhigh sera (results are given with ± standard errors of the means [SEM]; 1way ANOVA was performed for each day postinfection based on percent weight lost
relative to starting weight using two independent experiments with 6 mice/group; results
are listed in Table 3). (C) We completed ELISAs to quantify total H1-reactive antibodies in
each of our pooled serum samples and found that there were different amounts of HA
antibodies in each serum pool. (D) We repeated passive transfer studies after normalizing
serum amounts so that equal amounts of HA antibodies were transferred. Mice that
received uninfected HAIhigh or uninfected HAIlow pooled sera (gray and blue lines,
respectively) were protected similarly against severe influenza disease, with mice that
received uninfected HAIhigh pooled sera recovering more quickly than mice that received
uninfected HAIlow pooled sera (results are given with ±SEM; 1-way ANOVA was performed
for each day postinfection based on percent weight lost relative to starting weight using
one independent experiment with 6 mice/group; results are listed in Table 4).
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Table 2.1

Table 2.1. Demographic characteristics of subjects enrolled in hospital-based
human cohort study.
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Table 2.2

Table 2.2. Logistic regression modeling of HA head and stalk antibody association
with protection. Logistic regression analyses using both unadjusted (HAI only and stalk
only) and adjusted (HAI plus stalk) models. Values represent log2 geometric mean titers
from two independent experiments. OR, odds ratio; CI, confidence interval.

67

68

in Fig. 5B. NS, not significant. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

calculated on the percent weight lost compared to the baseline for each group each day. Data in this table are depicted

correction for multiple comparisons performed for each day post-infection. The P value for each comparison is reported,

Table 2.3. One-way ANOVA results for passive transfer normalized by volume. One-way ANOVA with Tukey's

Table 2.3
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are depicted in Fig. 5D. NS, not significant. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001.

reported, calculated on the percent weight lost compared to the baseline for each group each day. Data in this table

correction for multiple comparisons performed for each day post-infection. The P value for each comparison is

Table 2.4 One-way ANOVA results for passive transfer normalized by HA titer. One-way ANOVA with Tukey's

Table 2.4

CHAPTER 3

NO EVIDENCE OF ANTIGENIC DRIFT IN THE PANDEMIC H1N1
HEMAGGLUTININ STALK DOMAIN THROUGHOUT A DECADE OF
SEASONAL CIRCULATION

This chapter will be submitted for publication as:

Shannon R. Christensen, Emily T. Martin, Joshua G. Petrie, Arnold S. Monto, Scott E.
Hensley. No evidence of antigenic drift in the pandemic H1N1 hemagglutinin stalk domain
throughout a decade of seasonal circulation.
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Section 3.1 - Abstract
An H1N1 virus caused an influenza virus pandemic in 2009 and has continued to circulate
seasonably in humans over the past decade. Upon infection with the 2009 H1N1 strain,
many humans produced antibodies against epitopes in the hemagglutinin (HA) stalk. HA
stalk-focused antibody responses were common among 2009 H1N1-infected individuals
because HA stalk epitopes were conserved between the 2009 H1N1 strain and previously
circulating H1N1 strains. Here, we completed a series of experiments to determine if high
levels of H1N1 HA stalk antibodies within the human population has led to antigenic drift
in the H1N1 HA stalk since 2009. We identified 6 amino acid substitutions that have
accrued in the H1N1 HA stalk since 2009. We completed enzyme-linked immunosorbent
assays, absorption-based binding assays, and surface plasmon resonance experiments
to determine if these substitutions affect antibody binding. Using sera collected from 230
humans (aged 21-80 years), we found that H1N1 HA stalk substitutions that have emerged
since 2009 do not dramatically affect antibody binding. Our data suggest that the HA stalk
domain of H1N1 viruses has remained antigenically stable over the past decade.
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Section 3.2 - Introduction
Influenza pandemics typically occur when a novel influenza strain crosses the
species barrier into human circulation and transmission. The limited immunological
memory within the population allows for unhindered spread of the novel virus, resulting in
pandemic-level morbidity and mortality rates [336]. Even after the population develops
robust immunity against the pandemic virus, it can continue to circulate seasonally by
evading previously elicited antibody (Ab) responses through the accumulation of
mutations in the viral membrane proteins hemagglutinin (HA) and neuraminidase (NA),
through a process called antigenic drift [337].
In 2009, a triple reassortment event occurred between H1N1 viruses from avian,
swine, and human lineages [197]. The novel reassortant precipitated an unusual H1N1
pandemic – unusual because H1N1 viruses had been continuously circulating seasonally
in humans since 1977, and had previously circulated in humans from 1918 to 1957 [336].
The head domain of the HA protein, the viral membrane protein responsible for viral entry
into the host cell, of the 2009 pandemic H1N1 (pH1N1) strain contained epitopes that were
antigenically more similar to the HA from the seasonal H1N1 (sH1N1) strains that
circulated in humans prior to 1957 [222, 338-340]. However, the HA stalk domain
remained relatively well-conserved compared to the HA stalk domain of modern circulating
sH1N1 viruses [338-340]. The conservation of the pH1N1 HA stalk domain resulted in an
unprecedented boosting of HA stalk antibody responses in humans [219]. The HA stalk
domain has traditionally been considered immunosubdominant among seasonal influenza
strains, with the majority of neutralizing antibody responses directed towards the HA head
[156]. However, monoclonal Abs (mAbs) isolated from individuals exposed to the pH1N1
strain, through either vaccination or natural infection, target the highly conserved HA stalk
domain, or the receptor binding site [217, 218, 341]. Most of the isolated mAbs could also
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bind modern sH1N1 viruses efficiently and demonstrated a high degree of somatic
mutations, indicating they were secreted from memory B cells recalled during pH1N1
exposure [217, 218, 341-343]. Many of these HA stalk-specific mAbs neutralized
antigenically distinct influenza viruses within and across influenza A group 1 and group 2
viruses [217, 218, 343], and a small number that could neutralize both influenza A and
influenza B strains [147, 283], in mouse and ferret models.
The potential for antibodies elicited against the HA stalk domain to confer broad
neutralization spurred the pursuit of an HA stalk-based universal influenza vaccine. The
HA stalk domain is an appealing target for a universal influenza vaccine for a number of
reasons. This domain is more constrained than the HA head, due to the pH-induced
conformational change required for viral-endosomal membrane fusion and successful
infection of a host cell [165], and therefore may not be as likely to experience antigenic
drift, unlike the HA head domain. Additionally, human challenge studies have correlated
HA stalk antibody titers with reduced viral shedding and number of symptoms [313], and
serological cohort studies have demonstrated that HA stalk antibodies are significantly
associated with protection against pH1N1 influenza infection in adults and children [344,
345].
Although the amino acid sequence of the HA stalk domain is more constrained
than the HA head [346], increased immune pressure may drive antigenic drift within this
domain. Indeed, the H1N1 HA stalk domain is able to undergo antigenic drift in vitro when
incubated with HA stalk-specific mAbs or human polyclonal serum [347]. The isolated HA
stalk escape mutants not only replicated well in vitro, but also retained pathogenicity in
vivo [347]. This is an important finding as it demonstrates greater plasticity in the H1N1
HA stalk domain and that these escape mutants can retain fitness and virulence, both
observations that challenge the perception of this domain as an immutable antigenic
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target. In this study we have harnessed nature’s own experiment of increased
immunological pressure against the well-conserved HA stalk domain, elicited by pH1N1,
to determine if antigenic changes have occurred.

Section 3.3 - Results
Amino acid substitutions have accrued in the H1 HA stalk domain
We analyzed the HA protein sequences of 2047 H1N1 influenza genomes for
amino acid substitutions that had gone to fixation in the stalk domain [348, 349]; these
sequences were obtained from circulating viruses ranging from the introduction of the
pH1N1 strain in early 2009 through April 2019. A total of seven amino acid substitutions
were identified (Figure 3.1) that accrued over a span of ten years of seasonal circulation
(Figure 3.1). Importantly, one of these amino acid substitutions was adjacent to epitope 1,
the dominant neutralizing epitope in the H1 HA stalk domain (Figure 3.1).
Amino acid substitutions do not reduce binding by antibodies in human polyclonal
serum
Antigenic drift is the accumulation of amino acid substitutions in a viral glycoprotein
that gradually alters that protein’s antigenicity [350]. Amino acid substitutions in antigenic
sites of HA can arise as a mechanism to escape antibody neutralization [351], or can be
stochastically selected by other factors to fine-tune HA function, such as altering pH of
fusion [352] or viral binding to host receptors [353]. To determine if the amino acid
substitutions identified in the pH1N1 HA stalk domain had accumulated as the result of
antigenic drift, we analyzed serum collected from 230 participants enrolled in a household
cohort study (Ann Arbor, MI, USA) during the 2011-2012 influenza season. Importantly,
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we selected this seasonal cohort because the majority of individuals would have been
exposed to the pH1N1 virus (either through natural infection or vaccination), but was
before the H1-dominated influenza season of 2013-14. Households consisting of at least
two adults and two children were enrolled prior to the start of the influenza season. Serum
specimens were obtained for the estimation of H1N1 HA stalk-specific antibody binding to
the pH1N1 HA stalk domain +/- the identified amino acid substitutions in modern
circulating H1N1 influenza viruses.
To test the effect on HA antigenicity of these amino acid substitutions, we
introduced five of the substitutions (HA1-A13T, HA1-I324V, HA2-E47K, HA2-S124N, and
HA2-E172K) into a 2009 pH1N1 headless HA stalk protein. The two remaining amino acid
substitutions (HA1-K283E and HA1-I295V) were not analyzed since the HA1 residues 283
and 295 sit closer to the HA head and are not in our headless HA construct. We quantified
relative titers of H1 stalk total IgG antibodies using enzyme-linked immunosorbent assays
(ELISAs) coated with either the 2009 pH1N1 HA headless stalk protein (abbreviated as
2009 stalk) or the 2009 pH1N1 HA headless stalk protein containing five amino acid
substitutions that have gone to fixation (abbreviated as 2019 stalk). We found that HA
stalk-specific antibodies in polyclonal human serum bound similarly to the 2009 and 2019
HA stalk constructs, with a relative 2009 stalk mean titer of 3052 and 2019 stalk mean titer
of 2560 (Figure 3.2). Additionally, the 2009 and 2019 stalk titers were significantly and
positively correlated (Figure 3.2), suggesting HA stalk antibody binding is not affected by
the amino acid substitutions.
We next performed surface plasmon resonance (SPR) with a subset of serum
samples to determine if the current amino acid substitutions reduced binding affinity (Kd).
Representative curves and associated relative Kd values are depicted in Figure 3.2 and
Table 3.1, respectively. We observed a minor decrease in relative KD value for the 2019
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stalk, compared to the 2009 stalk (Table 3.1). However, all relative Kd values were 100%
correlated between the 2009 and 2019 stalk (Figure 3.3). Taken together, these results
indicate that the amino acid substitutions in the H1 HA stalk domain do not alter antibody
affinity.
To determine if the slight reduction in HA stalk-specific antibody titers and relative
Kd values observed in the previous experiments for the 2019 HA stalk were due to true
alterations in antibody binding, rather than assay-specific variability between the two
different antigens used, we completed additional absorption assays. Cells transfected
with the 2009 or 2019 stalk constructs containing a transmembrane domain were
incubated with a subset of serum samples to absorb out HA stalk-specific Abs; the
unbound fraction was then isolated and tested by ELISA against both the 2009 and 2019
HA stalks. If HA stalk antibody binding was reduced by the presence of the HA
substitutions in the 2019 stalk, some HA stalk antibodies would remain in the unbound
fraction of the 2019 absorption, and these could be detected by ELISA against the 2009
stalk. We quantified HA stalk titers of the unbound fraction of each absorption condition
against both the 2009 and 2019 HA stalk constructs by ELISA. We observed that both the
2009 and 2019 stalk efficiently absorbed all HA stalk-specific antibodies from each serum
sample (Figure 3.4), indicating HA stalk antibody binding is not greatly reduced by the
amino acid substitutions.

Section 3.4 - Discussion
The selective forces acting on the HA head and resultant antigenic drift of this
domain are relatively well-studied [191, 281, 298, 353, 354]. However, much less is known
about evolution within the HA stalk domain, despite this being a major target for the
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development of universal influenza vaccine strategies. Sequence alignments reveal that
circulating H1N1 viruses are accruing amino acid substitutions in the HA stalk domain over
time (Figure 3.1). However, our data indicates that the presence of these amino acid
substitutions do not abrogate binding or reduce affinity of HA stalk-specific antibodies in
human polyclonal serum in a biologically relevant manner (Figures 3.2, 3.3, and 3.4),
suggesting these substitutions are not selected for immune escape. While it is possible
these substitutions can simply be attributed to the inherently error-prone function of the
RNA polymerase, there are two alternative considerations for why these amino acid
substitutions may have been positively selected.
Amino acid substitutions can be selected as a means to improve HA function.
Indeed, one of the HA stalk amino acid substitutions that went to fixation early on, E47K,
has been closely studied for its effect on viral function [352]. The E47K substitution
increased both acid and thermal stability in vitro, and also increased pathogenicity in vivo
[352]. While mechanistic studies have not been conducted on the other amino acid
substitutions that have arisen in the H1 HA stalk domain, it is possible they also contribute
to fine-tuning of HA function.
Another possibility is that these substitutions in the HA stalk arose to compensate
for antigenic changes within the HA head domain, a mechanism of viral evolution that has
previously been identified in the highly pathogenic avian influenza virus subtype H5N1
[355]. Amino acid substitutions that mediate antigenic escape often incur pleiotropic
effects, such as altered binding to sialic acid, the host cellular receptor for influenza, or
decreased protein-folding stability [356-361], which in turn decrease viral fitness. In many
cases viral fitness can only be restored by compensatory mutations in the HA or NA
proteins that have opposing effects [357-359, 361-364]. Many compensatory mutations
are neutral and will arise through random drift first [365], thus allowing an otherwise
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deleterious antigenic mutation to arise, or the two mutations may occur simultaneously.
As such, the evolution of compensatory mutations can lead to entrenchment, the inability
of a substitution to revert to its ancestral state without deleterious effects [366].
While the findings presented in this study do not negate the potential for antigenic
drift to occur within the HA stalk domain once immunological pressure is increased if HA
stalk-based universal vaccines are deployed, they do support the HA stalk domain as a
durable target for a universal influenza vaccine. Future studies should focus on the
durability of the HA stalk domain after immunization with vaccine platforms designed to
elicit an HA stalk-specific immune response, as well as the persistence of this response
in the face of subsequent exposures to similar influenza strains that may revert the
immune response back towards the immunodominant HA head domain.
Section 3.5 - Materials and Methods
Human subjects: During the 2011-2012 influenza season, adult (≥18 years) participants
were prospectively enrolled in an observational, household cohort design study of
influenza vaccine effectiveness. All participants provided informed consent and completed
an enrollment interview. Influenza vaccination status was defined by self-report and
documentation in the electronic medical record and Michigan Care Improvement Registry
(MCIR). All specimens were collected prior to the start of the influenza season. Studies
involving humans were approved by the Institutional Review Boards of the University of
Michigan and University of Pennsylvania. All experiments (ELISAs, absorptions, and
surface plasmon resonance) were completed at the University of Pennsylvania using
deidentified sera.
Recombinant HA proteins: Plasmids encoding the 2009 H1 HA stalk were provided by
Adrian McDermott and Barney graham from the Vaccine Research Center at the National
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Institutes of Health. The sequence from the 2009 H1 HA stalk construct was used to
design a Gblock of the 2019 H1 HA stalk that incorporated five amino acid substitutions
(HA1-A13T, HA1-I324V, HA2-E47K, HA2-S124N, and HA2-E172K) +/- a transmembrane
domain and was ordered from Integrated DNA Technologies. The sequence from the 2009
H1 HA stalk construct was used again to generate a Gblock containing a transmembrane
domain attached to the 2009 H1 HA stalk. All Gblocks were cloned into the pSport6 vector
for expression. The headless HA stalk proteins not containing the transmembrane
domains were expressed in 293F cells and purified using nickel-nitrilotriacetic acid
agarose (no. 1018244, Qiagen) in 5-ml polypropylene columns (no. 34964; Qiagen),
washed with 50 mM Na2HCO3, 300 mM NaCl, and 20 mM imidazole buffer at pH 8. The
protein was then eluted in 50 mM Na2HCO3, 300 mM NaCl, and 300 mM imidazole buffer
at pH 8. Purified protein was then buffer exchanged into phosphate-buffered saline (PBS;
no. 21-031-CM; Corning). Some of each H1 HA stalk protein was aliquoted and stored at
-80C. The remaining protein was then biotinylated using the Avidity BirA-500 kit (no.
BirA500) and stored in aliquots at -80C.
MAbs: Plasmids encoding the human mAb CR9114 were provided by Patrick Wilson at
the University of Chicago. CR9114 was expressed in 293T cells and purified 4 days postinfection using NAB protein A/G spin kits (no. 89950; Thermo Fisher).
Headless HA ELISAs: Headless HA ELISAs were performed on 96-well Immunlon 4HBX
flat-bottom microtiter plates (no. 3855; Thermo Fisher) coated with 0.5 ug/well of
streptavidin (no. S4762; Sigma). We completed total IgG headless HA ELISAs (using both
the 2009 and 2019 stalks) with all serum samples. A detailed protocol has been previously
described elsewhere [344]. In brief, headless HA stalk proteins were diluted in biotinylation
buffer to a concentration of 0.25 ug/ml and 50 ul was added to each well. Wells were
blocked with 150 ul of biotinylation blocking buffer. Serum samples were serially diluted in
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biotinylation buffer (starting at 1:100 diltiion), then added to the ELISA plates. The human,
HA stalk-specific mAb CR9114 was used as a plate control, starting at 0.03 ug/ml, to verify
equal coating of plates and to determine relative serum titers. Peroxidase-conjugated goat
anti-human IgG (no. 109-036-098; Jackson) was added at 50 ul/well. Finally, SureBlue
TMB peroxidase substrate (no. 5120-0077; KPL) was added to each well and the reaction
was quenched with the addition of 25 ul/well of 250 mM HCl solution. Each step was
incubated for an hour at room temperature on a rocker. Plates were extensively washed
with PBS (no. 21-031-CM) and 0.1% Tween 20 between each step using a BioTek 405
LS microplate washer. Relative titers were determined using a consistent concentration of
the CR9114 mAb for each plate and each HA stalk construct, and reported as the
corresponding inverse of the serum dilution that generated the equivalent optical densities
(OD). Each ELISA was performed a minimum of two times.
Absorption ELISAs: Absorption ELISAs were completed using a randomly selected
subset of serum samples. 293F cells were split to a 1e6 cells/ml density in 500 mL (160
ml cell culture volume) vented tissue culture flasks (no. 431145; Corning) on the day of
transfection. 293F cells were transfected using 1 ml Opti-MEM (no. 31985-070; Gibco),
320 ul 293Fectin (no. 12347-019; Gibco), and 160 ug plasmids containing the H1 HA stalk
constructs with a transmembrane domain, or a mock transfection was performed. The
cells were incubated at 37C, shaking at 800 rpm, for three days. The cells from each
transfection condition were collected, spun down at 300 xg for 5 minutes, then resuspended in 30 mls FreeStyle 293 Expression Medium (no. 12338018; Thermo Fisher).
An aliquot of cells was taken for counting and the cells were spun again at 300 xg for 5
minutes, then re-suspended in an appropriate volume of FreeStyle 293 Expression
Medium (no. 12338018; Thermo Fisher) to obtain a concentration of 1e8 cells/ml. Cells
and individual serum samples at a 1:10 dilution were mixed in a 1:1.1 ratio (to
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accommodate for the substantial volume of cells) to ensure a gross excess of antigen was
present. The serum/cell mixture was incubated in a 96-well U-bottom plate (no. 353077;
Corning) for 1 hour on a plate shaker set to 800 rpm. The 96-well plate was then
centrifuged at 2000 RPM for 5 minutes and the supernatant transferred to another 96-well
U-bottom plate (no. 353077; Corning) and centrifuged a second time for 5 minutes at 2000
rpm to remove all cells. The supernatant was transferred into labeled microcentrifuge
tubes (no. 05-408-129; Thermo Fisher) and stored at 4C until a standard headless HA
ELISA (described above) could be performed. As an absorption control, the human mAb
CR9114 was incubated under the same absorption conditions at a concentration of 2
ug/ml. Each absorption ELISA was performed a minimum of two times.
Surface plasmon resonance. All SPR experiments were performed on the BIACore
3000 instrument by GE Healthcare. The LS Sensor Chip NTA (no. BR-1004-07; GE
Health Sciences) surface was conditioned by injecting 350 mM EDTA (diluted from 0.5
M, pH 8 stock, no. 15575020; Thermo Fisher) at 10 ul/min for 1 minute followed by
extensive washing with running buffer to remove residual EDTA. To ensure all EDTA
was removed, a subsequent washing step using 50 mM NaOH, injected at 10 ul/min for
1 minute was performed. The chip surface was then prepared for antigen capture by
injecting 0.5M NiCl2 at 10 ul/min for 1 minute. The HIS-tagged 2009 and 2019 HA stalk
proteins, previously diluted to 2.5 ug/ml in 1x HBS-P buffer (0.01 M HEPES (no. 25-060Cl; Corning) pH 7.4, 0.15 M NaCl, 0.005% v/v Polysorbate 20 (Tween 20) (no. BP337100; Thermo Fisher)), were immobilized onto separate channels of the LS Sensor Chip
NTA (no. BR-1004-07; GE Health Sciences) at 5 ul/min with a target density of 350
response units, followed by a 20 minute incubation. Serum samples, previously diluted
to concentrations of 1:100, 1:400, and 1:1600 in 1x HBS-P buffer, were injected at 20
ul/min for 150 seconds over the immobilized rHA stalk chip channels or the reference
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chip channel, followed by a 400s dissociation phase. Each step was followed by an
extensive washing cycle using 1x HBS-P buffer. For kinetic analysis, injections over
reference cell channels and injections with buffer only were subtracted from the data.
Association rates (ka), dissociation rates (kd), and equilibrium dissociation constants (Kd)
were calculated by aligning the curves to fit a Langmuir 1:1 binding model using
BIAevaluation 4.1 software. To obtain a relative concentration of H1 HA stalk-specific
antibodies in each polyclonal serum sample used, we performed an HA stalk ELISA
(according to methods described above) to determine the serum dilution required to
achieve an OD equivalent to 2 nM of CR9114. These relative serum concentrations were
used as input for the Langmuir 1:1 model for each serum sample concentration. Each
SPR experiment was performed in triplicate, using a subset of serum samples.
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Figure 3.1
A.

B.

Figure 3.1. Amino acid substitutions have accrued in the HA stalk domain. Analysis
of entropy at each amino acid position in 2047 H1N1 HA genomes from 2009 - 2019 using
Nextstrain.org. (A) Seven amino acid substitutions have entered fixation in the seasonal
H1N1 HA stalk domain. Black outline depicts location of epitope 1. (B) Timeline of when
amino acid substitutions entered fixation in the seasonal H1N1 HA stalk domain.
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Figure 3.2

Figure 3.2. Amino acid substitutions do not greatly reduce binding by antibodies in
human polyclonal serum. Relative H1 HA stalk titers for the 2009 and 2019 headless
HA stalk constructs were determined by ELISA. Each dot represents a single serum
sample (n = 230). (A) Relative mean stalk titers are 3052 and 2560 for the 2009 and 2019
H1 HA stalk domain, respectively. (B) 99.47% of samples demonstrated <2-fold difference
in titers between the 2009 and 2019 H1 HA stalks. The ratio of the titers (2009/2019) were
determined using geometric mean titers of two independent experiments. (C) Relative
titers between the 2009 and 2019 HA stalk are strongly and significantly correlated
(Spearman correlation, r = 0.9788, p < 0.0001).
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Figure 3.3
A.

B.

C.

Figure 3.3. Amino acid substitutions do not decrease affinity of H1 HA stalk-specific
antibodies in human polyclonal serum. A subset of serum samples (n = 16) were
analyzed for relative Kd values against the 2009 and 2019 headless HA stalk by surface
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plasmon resonance (SPR). (A) Representative serum sample binding and dissociation
curves by SPR (blue line = 2009 stalk, red line = 2019 stalk). (B) All samples demonstrated
<2-fold difference in relative Kd values between the 2009 and 2019 H1 HA stalks. The
ratios of the titers (2009/2019) were determined using geometric mean Kd values of two
independent experiments. Each dot represents a single serum sample. (C) Relative Kd
values for the 2009 and 2019 stalks demonstrated highly significant correlation (Spearman
correlation, r2 = 1.00, p < 0.0001). Correlation was performed on geometric mean titers of
two independent experiments. Each dot represents a single serum sample.
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Figure 3.4
B.

Figure 3.4. Amino acid substitutions in the H1 HA stalk domain do not decrease
absorption efficiency of antibodies from human polyclonal serum. H1 HA stalk titers
for the 2009 and 2019 headless HA stalk constructs were determined by ELISA. (A)
Unbound fraction of serum was isolated post-absorption with either the 2009 or 2019
headless HA stalk constructs, or with mock transfected cells. HA stalk titers for the 2009
and 2019 absorption conditions are depicted as % area under the curve (AUC) relative to
the mock absorption condition. All titers were below the limit of detection in the 2009 and
2019 absorption conditions.
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Table 3.1

*Relative to 20 nM CR9114

Table 3.1. Relative Kd values for H1 HA stalk-specific antibodies in human
polyclonal serum. Relative concentrations of H1 HA stalk-specific antibodies were
determined by ELISA using a standard curve generated from the H1 HA stalk-specific
mAb CR9114. Each serum sample was assessed by surface plasmon resonance (SPR)
against the 2009 and 2019 headless HA stalk. Relative Kd values represent the geometric
mean value of two independent experiments.
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CHAPTER 4

CONCLUSIONS AND FUTURE DIRECTIONS

Section 4.1 - Summary
Influenza viruses are a persistent threat to public health, and our current vaccine
strategy is not consistently effective in protecting the population from the considerable
morbidity and mortality of seasonal influenza infections. We have been in a continual ‘arms
race’ since the first influenza vaccine was developed in the 1940s. The cycle of creating
a vaccine based on circulating viral strains that undergo antigenic drift, followed by
updating those vaccines and the rise of new antigenic variants, has continued for over
seventy years. The problem is that our current vaccine strategy elicits antibodies that
primarily target a protein domain that is formidable in its ability to retain functionality while
constantly altering its form through antigenic drift. Additionally, the strain-specific HA head
antibodies induced by seasonal influenza vaccines are not expected to protect against
novel influenza viruses that jump into human circulation through reassortment events. The
influenza field has been diligently working to address this problem since the 1970s, with
the goal of developing a universal influenza vaccine that can provide protection against
drifted seasonal strains and potential pandemic strains alike.
The approach to developing a universal influenza vaccine sounds deceptively
simple: identify a viral protein that is highly constrained between influenza A strains and
develop a vaccine platform that will elicit antibodies against that protein. However, to
successfully develop a more persistent and broadly protective vaccine, we must consider
not only the immunogenicity of a viral target, but also investigate the polyclonal antibody
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response against target candidates to understand how immune history affects the
dynamics of immune responses, as well as the durability of antibody-mediated protection
against these targets.
In Chapter 2 we demonstrated for the first time that HA stalk antibody titers are
associated with protection against influenza infection and severe disease, though the
protective effect size was smaller than that of HA head antibodies (Figure 2.1 and Table
2.2). Despite their association with protection, we were unable to identify a clear threshold
of protection for HA stalk antibody titers, which will be an important consideration in the
future for use as a surrogate marker of protection. However, this lack of a clean cutoff
between uninfected and infected individuals can also occur with HA head antibody titers
[367], even though the HAI titer of >1:40 is the widely accepted threshold of protection
[241, 242]. As discussed in Chapter 1, identifying true correlates of protection is difficult
and we often have to turn to surrogate serological markers, such as antibody titers. The
caveat with ELISA titers, though specific for the HA stalk domain, is that we are simply
measuring prevalence, rather than functionality. However, we also demonstrated that
polyclonal serum from individuals with low HA head antibody titers was able to confer
moderate protection against severe disease in mice when challenged with pH1N1,
demonstrating the functionality of the HA stalk antibodies quantified by ELISA. This is an
important component of establishing a true correlate of protection and should be
considered in future studies to assess HA stalk antibody titers as a surrogate marker of
protection. Importantly, a study was published shortly after ours using a much larger cohort
that supported our findings and demonstrated the independent association of HA stalk
antibodies with protection against influenza infection in both adults and children [345].
Finally, we determined that the overall ratio of HA stalk antibody isotypes is fairly similar
between uninfected and infected individuals in pre-infection serum. However, we found
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that uninfected individuals have significantly higher titers of serum IgG1 and IgA antibodies
compared to infected individuals (Figure 2.3). Given that different antibody isotypes are
associated with different Fc-receptor mediated effector functions, a prevailing functional
characteristic of HA stalk antibodies, this observation warrants further investigation.
Once we determined that HA stalk antibodies were associated with protection
against influenza infection, we turned our attention to the possibility for antigenic drift
within the HA stalk domain. Exposure to the 2009 pH1N1 strain caused the preferential
boosting of HA stalk-specific antibodies in many individuals [218, 219, 287], providing a
natural experiment to determine if increased immune pressure against this domain would
generate amino acid substitutions in the HA stalk domain. In Chapter 3 we hypothesized
that amino acid substitutions would have accumulated in the H1 HA stalk since 2009, and
that these substitutions would affect the antigenicity of this domain. We identified seven
amino acid substitutions in the HA stalk domain of the 2019 H1N1 strain relative to the
2009 pH1N1 strain (Figure 3.1), when this viral lineage was originally introduced into
humans. We engineered headless HA stalk constructs from the 2009 and 2019 H1N1
viruses to use as tools to elucidate if the amino acid changes were antigenically relevant,
using polyclonal human sera. We found that the overall binding and specific affinities of
HA stalk antibodies were not decreased in a biologically relevant manner by the amino
acid substitutions present in the 2019 HA stalk (Figures 3.2, 3.3, and 3.4), suggesting the
HA stalk domain has not experienced antigenic drift in its ten-year history of human
circulation. This conclusion is highly relevant to the development of current HA stalk-based
universal influenza vaccines, as it demonstrates the HA stalk is a durable target for long
term antibody-mediated immunity.
These two projects revealed new, supporting evidence for the HA stalk domain as
a desirable candidate for a universal influenza vaccine. These findings also provide new
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avenues for basic research into the functional characteristics of HA stalk antibody isotypes
and consequences of amino acid substitutions for non-neutralizing stalk antibodies, as
well as translational investigations on the induction of HA stalk antibodies to protective
thresholds and effects of immune history on induction. This chapter will focus on the
broader implications of our work for the development of an HA stalk-based universal
influenza vaccine and the future directions of both projects.

Section 4.2 - Protective immune responses against the HA stalk domain
There is still much to learn about the induction and functionality of HA stalk
antibodies, as well as the need to establish correlates of protection that can be reliably
tested in a high through-put manner. In this section I will address each of these outstanding
areas of research and potential avenues of investigation to move towards the ultimate goal
of developing a truly universal influenza vaccine.
HA stalk antibody titers as a novel correlate of protection
In Chapter 2 we demonstrated that HA stalk antibody titers are associated with
protection against influenza infection in humans as measured by ELISA. However, it is
imperative that we develop novel, reliable assays to quantify the protective effects of HA
stalk antibodies and an associated titer that can be used as a surrogate marker for a true
correlate of protection. Agencies responsible for immunization recommendations, such as
the US Advisory Committee for Immunization Practices and the World Health
Organization, rely on established thresholds of surrogate markers as an immunological
correlate to differentiate between individuals considered to be immunologically protected
versus susceptible [368, 369]. In terms of vaccine development, demonstration of an
immunological correlate for candidate vaccines is quickly becoming a fundamental
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objective in clinical trials and epidemiological studies, so a protective threshold for HA
stalk antibodies may be required for future HA stalk-based universal influenza vaccine
trials. Determination of a protective threshold for HA stalk antibody titers can be used as
an indicator for successful seroconversion in vaccine trials and will simplify clinical trials
of the vaccine in new populations, such as age- and risk-groups, by providing an
immunogenicity endpoint that can help avoid the need of a large-scale efficacy trial.
Identification of an HA stalk antibody correlate is also important for the comparison of old
(seasonal) to new (universal stalk-based) vaccines, as well as assessment of the duration
of protection conferred by these vaccines. Ultimately, an established protective threshold
will be a crucial component for the success and licensure of HA stalk-based universal
influenza vaccines. Additionally, the FDA offers accelerated approval for applications that
include correlates that are deemed “reasonably likely” to predict clinical benefits [370].
As previously mentioned, current seasonal influenza vaccines elicit strain-specific
antibodies that target the HA head domain and are quantified using HAI assays. HAI titers
of 1:40 have been correlated with a 50% reduction in risk of infection [241, 242]. Achieving
this HAI titer threshold determines successful seroconversion in seasonal influenza
vaccine trials and is used to demonstrate vaccine effectiveness for the licensing of new
influenza vaccine platforms [242, 367, 371]. However, HAI assays do not detect antibodies
that bind to the HA stalk domain. In Chapter 2 we used ELISAs to quantify HA stalkspecific antibody titers and to demonstrate an association with protection. However,
ELISAs only measure antigen binding and cannot predict the functionality of these
antibodies. HA stalk antibodies can mediate protection through several different
mechanisms, and it is these functional subsets that need to be quantified and used as a
surrogate marker of protection. The functionality of some HA stalk antibodies may be
detected through MN studies, but the results will be confounded by the presence of HA
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head antibodies when using whole human serum. Some studies have used influenza
viruses expressing chimeric HAs that have an exotic head domain to detect stalk-only
neutralization in polyclonal human serum [372], but these results can still be confounded
by cross-reactive antibodies specific for the highly-conserved RBS of the HA head domain,
or by antibodies targeting other viral domains. Still other studies have used reporter
assays to detect Fc-receptor mediated effector functions, such as the NK cell-mediated
ADCC assay discussed in Chapter 2, or neutrophil-mediated phagocytosis assays [173].
The caveat to these types of assays is they each only measure a single function of HA
stalk antibodies. HA stalk antibodies are often multi-functional and may rely upon the
presence of their innate cellular partners to realize their full protective potential by
mediating Fc-receptor effector functions. It is therefore imperative to develop novel, highthroughput assays or modifications to current assays to quantify the protective effects of
HA stalk antibodies. This will likely rely upon establishing correlations between in vitro
functional assay(s), and in vivo protection; ideally, the in vitro assays would detect Fcreceptor mediated effector functions, as well as traditional neutralization. One approach
could be the isolation of HA stalk antibodies from human sera that can be used in in vitro
binding and functionality assays, then correlated with protection in vivo. We are currently
developing a protocol that will allow fractionation of HA stalk antibodies in human sera:
serum samples are incubated with streptavidin-coated beads decorated in biotinylated
‘headless’ HA stalk constructs for the absorption of HA stalk-specific antibodies, the beads
are isolated and washed, and the HA stalk antibodies are eluted. The HA stalk antibody
fraction can then be used in traditional functional assays (MN, ADCC, and ADCP) and/or
passively transferred into mice expressing humanized Fc-receptors. The functional assay
titers and weight loss from the mouse challenge model could then be correlated. This
approach would eliminate the confounding presence of neutralizing HA head antibodies

94

in MN assays and would allow simultaneous detection of all protective mechanisms of
action mediated solely by HA stalk antibodies. While these proposed studies are more
complex than the current HAI method of detecting seroconversion, they do allow for
detection of the multi-faceted protection that is mediated by HA stalk antibodies.
Additionally, if specific surrogate markers from the different functional assays are identified
as correlating with protection from the in vivo studies, this could establish a simpler, more
high-throughput means to determine successful seroconversion and to assess vaccine
effectiveness.
Induction of protective HA stalk antibody responses
Although HA stalk antibodies are associated with protection against influenza
infection, the effect size, or reduction in risk of infection, is ~40% lower for HA stalk
antibodies as compared to HA head antibodies (Table 2.2). Additionally, polyclonal human
sera with low HA head antibodies only conferred protection against severe disease, but
not against infection, when passively transferred into Fc-receptor humanized mice (Figure
2.5, Tables 2.3 and 2.4). Therefore, a reasonable concern for an HA stalk-based universal
vaccine is whether or not it can induce functional HA stalk-specific antibodies to titers high
enough to confer adequate protection against influenza infection in humans.
HA stalk antibodies can be efficiently elicited by vaccine platforms that redirect the
immune response towards the immunosubdominant HA stalk domain, using either HAs
with divergent globular head domains (through chimeric HAs or exposure to exotic avian
influenza strains) [291, 293, 294, 373] or by removing the HA head completely with a
headless HA stalk construct [273-275, 292]. Additionally, in vitro ADCC and ADCP assays
have been used to demonstrate the functionality of HA stalk antibodies induced by these
methods. However, to tailor vaccines towards the efficient induction of potently
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neutralizing and broadly cross-reactive HA stalk-specific immune responses, we should
carefully examine what drives enhanced immunogenicity of vaccine antigens and consider
elicitation of cellular immune responses into future vaccine designs.
Modulation of antigen immunogenicity
The strategy used for the expression of recombinant proteins used in vaccines is
an important consideration. Recombinant HA proteins can be prepared from mammalian
cells, insect cells, bacterial cells, and yeast [168, 374, 375]. Each of these expression
systems contain different post-translational modification pathways, resulting in different
levels of glycosylation on the HA protein. Variation in the glycosylation status of the HA
protein may influence the protective capacity of induced HA stalk-specific antibodies and
their ability to bind antigen, as glycans on the vaccine antigen may shield neutralizing
epitopes. A recent study examined the effects of varying numbers of glycosylation sites
on the antigenicity of an H1 HA stalk protein. This group determined that a monoglycosylated HA stalk, expressed in yeast, could induce higher levels of IgG2a antibodies
in mice that mediated greater ADCC activity, compared to a fully glycosylated H1 HA stalk
expressed in mammalian cells [376]. Additionally, the neutralization activity of the monoglycosylated HA stalk antisera was greater against heterologous H1N1 and H5N1 viral
strains, compared to the antisera elicited by the fully glycosylated construct [376].
Importantly, the binding of antibodies was equivalent between the antisera elicited by the
mono-glycosylated and fully glycosylated H1 HA stalk. Additionally, the viruses used in
the neutralization assays would have been fully glycosylated in these assays, as they were
performed in infected mammalian cells [376]. Taken together, these data indicate that
mono-glycosylation enhances immunogenicity of the HA stalk domain and the elicited
antibodies retain their functionality in the presence of a fully glycosylated HA protein.
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Future work should include in vivo challenge studies, using homologous and heterologous
strains, in mice previously immunized with either the fully glycosylated or monoglycosylated HA stalk. This would determine if the in vitro functionality observed in this
study correlates with in vivo protection.
An additional line of study that should be pursued is the difference in glycosylation
state between Group 1 and Group 2 influenza subtypes. Group 2 HAs, but not Group 1
HAs, contain a glycosylation site that sits adjacent to the highly conserved epitope 1
(Figure 1.3) in the HA stalk domain. This glycosylation site has been attributed to the
difficulties in neutralizing Group 2 influenza subtypes. Therefore, it will be important to
determine how glycosylation affects the immunogenicity of different HA subtypes, and the
subsequent functionality of antibodies when faced with a fully glycosylated HA in the
context of infection.
Induction of cellular immunity
In addition to neutralizing antibody responses, HA stalk-specific cellular responses
also contribute to protective immunity against influenza virus. Mouse studies have
demonstrated that induction of CD8 T cell responses targeting an epitope in the HA stalk
domain of the PR8 IAV protects against lethal challenge with heterologous viruses [377].
Antibody-independent, antigen-specific CD4 T cells with cytotoxic characteristics have
also been correlated with viral clearance and decreased disease severity [378-380].
Epitopes within the HA stalk domain have been identified that induce cytotoxic,
polyfunctional CD4 T cells that support a TH1 response through the production of IFN-γ
and confer partial protection against lethal pH1N1 challenge in mice [381]. Taken together,
these studies indicate that designing an HA stalk-based universal influenza vaccine that
can efficiently induce cellular immunity, as well as humoral immunity, may be highly
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desirable. Indeed, universal influenza vaccines designed to elicit T cell responses to
augment antibody responses against influenza viral targets have already demonstrated
robust cross-protective anti-influenza immune responses [382]. However, the risk of
immunopathology is high when inducing potent effector functions. Since HA stalk
antibodies can mediate inflammatory effector functions such as ADCC, we must carefully
consider the implications of intentionally eliciting cytotoxic CD4 and CD8 T cell effector
functions as well and balance the protective effects against any associated tissue damage
resulting from such a response.
Effector functions of HA stalk antibodies
As discussed in Chapter 1, different antibody isotypes mediate different effector
functions through variable binding to the Fc-receptors of innate immune cells. In Chapter
2, we observed that uninfected individuals had elevated titers of serum IgA antibodies
compared to infected individuals (Figure 2.3). This was an intriguing observation because
while mucosal anti-influenza IgA titers have been shown to be important in reducing
transmission events between infected guinea pigs [324] and to inhibit viral egress [325],
little is known about the contribution of serum IgA antibodies to protection from influenza
infection. One study revealed that HA stalk-specific IgA antibodies neutralized influenza
virus more potently than IgG antibodies with identical variable regions, and that memory
B cells isolated from human peripheral blood were more likely to be stalk-specific when
secreting IgA antibodies, compared to those secreting IgG antibodies [326].
Understanding how antibody isotype contributes to functionality could open the door for
universal influenza vaccines to steer antibody induction towards functionally-tailored
responses.
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For example, a recent pre-clinical study for a Mycobacterium tuberculosis (Mtb)
vaccine reported the use of a liposomal adjuvant that efficiently activates DCs and induces
a TH1 biased CD4 T cell and antibody response [383]. The study combined the liposomal
adjuvant with a Mtb protein subunit to evaluate a prime-boost immunization strategy in
mice, using a combination of parenteral and intrapulmonary administration routes. This
study provided compelling evidence that this immunization strategy induced high levels of
antigen-specific IgA and polyfunctional CD4 T cells in both the lung mucosa and in
systemic circulation [383]. Another example can be found in human immunodeficiency
virus (HIV) literature. A study using pro-inflammatory cytokines as an adjuvant with an HIV
peptide antigen, administered intranasally to mice, demonstrated strong induction of
mucosal and systemic IgA titers [384]. Studies such as these illustrate how vaccines can
be tailored through the use of adjuvants and routes of administration to induce not only
specific antibody isotypes that can mediate potent Fc-receptor effector functions, but also
to direct the immune landscape towards a highly functional TH1 response.
Fc-receptor mediated effector functions are not regulated solely through antibody
isotype. Both the isotype and Fc-glycoform composition of an antibody determines which
Fc-receptor interactions will occur, and thus informs effector functions. The Fc domain of
antibodies all contain a single biantennary N-glycan attached to the asparagine residue at
position 297 in the CH2 domain of the heavy chains. The N-glycans are often fucosylated
and contain a bisecting N-acetylglucosamine (GlcNAc), but vary in the number of antenna
galactose and sialic acid residues [385]. Fc-glycosylation states of influenza-specific IgG1
antibodies are altered upon vaccination with seasonal H1N1 in healthy adults and children;
immunization induced higher levels of galactosylation and sialylation, and decreased the
levels of bisecting GlcNAc [386]. Importantly, IgG1 Fc N-glycans containing a bisecting
GlcNAc have been shown to increase ADCC potency in vitro [387, 388], while increased
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galactosylation has been shown to result in weak Fc-receptor interactions [389]. Taken
together, these data suggest that current seasonal influenza vaccines result in Fc Nglycan changes that are inhibitory for Fc-effector functions mediated by anti-influenza
IgG1 antibodies. In Chapter 2 we observed that IgG1 HA stalk-specific antibodies were
elevated in uninfected individuals, comprising most of the total IgG response that was
associated with protection against infection (Figure 2.3). This implies that IgG1 stalk
antibodies functionally contribute to protection from infection. Considering most HA stalk
antibodies mediate Fc-effector functions, this could have deleterious consequences for an
HA stalk-based vaccine. Therefore, it would be beneficial to elucidate the Fc-glycan
composition on HA stalk-specific antibodies during resting-state and how the Fc-glycan is
altered with an HA stalk-focused influenza vaccine. Fc-glycan analysis using human or
murine serum would be fairly straight-forward, as the required tools and reagents are
readily available. In brief, serum samples could be enriched for HA stalk antibodies
through the absorption technique described earlier, forgoing the elution step. The Fc
domain of the antibodies could be isolated by papain digestion (an important step as the
Fab region of antibodies also contain several N-linked glycosylation sites). The Fc fraction
could then be treated with PNGase F to cleave the N-linked glycans. Once the Fc-domain
N-linked glycans are isolated, there are several techniques available for glycan analysis,
including mass spectrometry, capillary electrophoresis, and HPLC. Glycan standards are
commercially available.
As discussed in Chapter 1, the memory B cell repertoire is the primary source of
HA stalk-specific antibodies [156, 217, 218]. Interestingly, recall of HA stalk-specific
memory B cells may be advantageous for the N-linked glycosylation state of HA stalk
antibodies and their mediated effector functions. Memory B cells have lower levels of
FUT8 expression [390], the enzyme required for adding fucose to the N-linked glycan
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structure, and therefore may induce higher levels of afucosylated antibodies. Afucosylated
mAbs have been used therapeutically for many years due to their increased binding affinity
for FcγRIIIA (CD16) [391], which mediates phagocytosis and ADCC [392], two of the
primary effector functions induced by HA stalk antibodies.

Section 4.3 - HA stalk domain as a durable target for a universal influenza vaccine
After determining the H1 HA stalk domain has not experienced antigenic drift in
the past decade, we posited in Chapter 3 that the amino acid substitutions in the HA stalk
domain might be compensatory for antigenic changes in the HA head domain. Several
mutations in the HA head domain that confer binding to human-type receptors have been
reported to decrease thermal or acid stability of HA, but this stability can be compensated
for when amino acid substitutions are introduced within the HA stalk domain [355, 393]. It
has also been shown that HA heat stability and pH of membrane fusion contributes to the
respiratory droplet transmissibility of influenza viruses in mammals [393, 394]. In this way,
compensatory mutations that do not themselves alter antigenicity can still contribute to
increased pathogenicity and even spill-over events that could initiate an influenza
pandemic. Often, compensatory mutations become “entrenched”, meaning the
substitution cannot be reverted back to its original state without deleterious effects on viral
fitness. This potential entrenchment could be exploited to elucidate the compensatory
nature of the amino acid substitutions in the 2019 H1 HA stalk domain through methodical
mutational analysis. A panel of single revertants could be assessed for decreased thermal
and pH stability using simple in vitro assays such as growth curves under different
temperature conditions and membrane fusions assays, respectively. The library of HA
stalk revertants could also be assessed for altered receptor binding affinity by surface
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plasmon resonance. The determination of the compensatory nature of the accumulated
H1 HA stalk domain amino acid substitutions will provide a better understanding of the
evolutionary landscape of influenza virus and may inform future rational vaccine design.
The HA stalk domain is not static - in Chapter 3 we showed evidence of amino acid
substitutions that have accrued, albeit slowly, during seasonal circulation (Figure 3.1).
Additionally, studies have demonstrated that the HA stalk domain can undergo antigenic
drift in vitro when incubated in the presence of HA stalk-specific mAbs or polyclonal human
serum [347]. Therefore, it is important to investigate the effects of increased immune
pressure elicited by HA stalk vaccine candidates on the evolution of the HA stalk domain.
Although I described the increase in HA stalk antibodies following the 2009 H1N1
pandemic as “nature’s experiment” to examine the possibility of antigenic drift within the
HA stalk domain, I have also illustrated in this chapter how the use of adjuvants,
administration route, and antigen immunogenicity can greatly affect the resulting immune
response. Therefore, an important consideration regarding the durability of the HA stalk
domain as a target for a universal influenza vaccine is the potential for antigenic drift to
occur under the specific immune conditions elicited by a vaccine candidate. This type of
study would be best performed using a ferret challenge model.
A ferret challenge model is likely to be a cost-effective and efficient method to
determine the effects of increased immune pressure on the HA stalk domain in vivo. If a
ferret model were to be pursued, this type of study should be performed in ferrets that had
previously recovered from an H1N1 infection, followed by immunization with an HA stalkbased influenza vaccine; this study design would best recapitulate prior exposure and the
resultant HA stalk antibody boosting in humans, along with any accompanying immune
responses elicited by the vaccine candidate. Transmission chains could be set up with the
ferrets, wherein the first ferret (D0) is infected artificially by nasal inoculation. The D0
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ferrets could then be co-housed with uninfected ferrets (R0) to create a direct transmission
line; this would have the added advantage of avoiding direct inoculation of in vitro cultured
strains, which have previously been shown to alter within-host viral diversity [395]. Once
the R0 ferret is infected, they can be co-housed with the next recipient ferret (R1). In this
way, transmission chains (R1-Rx) can be established to allow for multiple passages of the
virus in the presence of boosted HA stalk antibodies. Ferrets could be sacrificed at each
stage of the transmission chain, respiratory tissues collected, and the viral HA sequences
analyzed for evidence of antigenic drift. This approach would allow for a more informed
and biologically relevant conclusion as to the possibility for antigenic drift within the HA
stalk domain.

Section 4.4 - Effects of immune history
An individual’s susceptibility to influenza infection appears to be shaped by their
very first influenza exposure through immune imprinting, an immune bias towards antigens
encountered early in life [204, 207, 208]. These initial biases can become more
entrenched by repeat exposures to diverse influenza antigens through the back-boosting
of memory B cells, rather than generation of a de novo antibody response [396]. It is
thought that the HA stalk domain is the driving force behind the group-specific imprinting
signatures that have been observed in epidemiological studies [208, 397]. Immune
imprinting can provide immunological benefits by conferring robust protection against
certain antigenic subtypes, particularly within the same phylogenetic group. Indeed,
certain birth cohorts have been spared from every modern influenza pandemic, protection
likely afforded by cross-reactive memory responses primed in childhood [222, 398-402].
Additionally, the influenza subtype circulating during a given birth-year can predict an
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individual’s reduction in risk for severe disease from novel, emerging avian influenza A
viruses within the same phylogenetic HA group [208].
Unfortunately, imprinting may have negative consequences as well. For example,
Gostic et al, demonstrated that 1968, the year when circulating viruses changed from
Group 1 to Group 2, is a demarcation line for susceptibility to severe disease from
emerging influenza strains. Individuals born before 1968 would have been imprinted with
a Group 1 virus, whereas those born after 1968 would likely have been imprinted by a
Group 2 virus. I highlighted earlier how this birth-year effect predicted reduced risk of
infection from emerging viruses within the same group, but the inverse is true as well.
Individuals born before 1968 demonstrated increased risk for severe disease by emerging
Group 2 viruses, while those born after 1968 were especially susceptible to Group 1
viruses [208]. Group 1 and Group 2 influenza A viruses have been co-circulating since
1977, so most individuals have been exposed to both virus sub-groups, suggesting that
imprinting may hinder the immune system’s ability to mount a strong protective response
against heterologous influenza viruses encountered later in life.
The absence of a protective response against influenza strains encountered later
in life is a concern for the efficacy of an HA stalk-based universal influenza vaccine. It
suggests that primary influenza exposure may inhibit or dampen the induction of a de novo
response against influenza exposures to heterosubtypic influenza virus strains. While the
mechanism behind this has not been fully elucidated, it has been suggested that “epitope
masking” could play a role [403, 404]. Pre-existing or rapidly secreted antibodies, as in the
case of a memory response, that recognize conserved stalk domains could sterically
hinder access to other B cell receptor epitopes; this ‘masking’ could contribute to blocking
de novo responses against unique, heterosubtypic stalk epitopes. Alternatively, as
discussed in Chapter 1, the preferential recall of memory B cells generated against
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influenza strains encountered early in life could be attributed to the lower activation
threshold of memory B cells and/or to the higher affinity of memory B cells for antigen,
compared to naïve B cells, resulting in reduced antigen availability for naïve B cells in a
germinal center response [213].
Is there a way to develop a truly universal influenza vaccine, one that provides
protection against both influenza A groups, if the human immune response is biased
towards the HA stalk domain of a certain subgroup? In naïve individuals, this could
potentially be addressed by using a bivalent vaccine containing the HA stalk domains from
Group 1 and Group 2 viruses; this approach would likely remove the antigenic hierarchy
and result in a balanced immune response to all included antigens. However,
seroprevalence for at least one influenza A virus is around 20% by 1 year of age, but
increases to 99% by 6 years of age [405], indicating vaccination would have to be carried
out very early in life for this approach to be successful. Unfortunately, for immunologically
experienced individuals, the immune bias towards the primary influenza strain exposure
continues to be a real concern. While we could likely tailor the influenza A HA stalk vaccine
group based on year of birth in an attempt to elicit a response against the strain not
encountered in childhood (Group 2 for individuals born before 1968 and Group 1 for
individuals born between 1968-1977), due to the co-circulation of both Group 1 and Group
2 influenza A viruses in humans, this would not be an option for individuals born after
1977.
There are a few avenues that could be pursued to overcome this hurdle of immune
imprinting. Increasing the dose of a vaccine has proven effective in seasonal vaccines
designed for the elderly [406, 407], but this would require administering vaccines tailored
to specific birth-year cohorts based on probability of initial influenza exposure, and so is
not likely to be an efficient or cost-effective approach. Development of an adjuvanted stalk-
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based vaccine might overcome pre-existing, imprinted immunity. Immunization with an
AS03-adjuvanted 2009 pH1N1 vaccine readily boosted HA stalk antibody titers, even in
the presence of high HA head antibody titers against the vaccine strain [408], suggesting
adjuvants might help circumvent imprinted immune responses. Finally, employing
unconventional vaccine platforms may improve de novo immune responses, even in the
presence of high concentrations of pre-existing HA stalk-specific antibodies. One preclinical platform that shows extraordinary promise is the nucleoside-modified, purified
mRNA lipid nanoparticle (mRNA-LNP) [312, 409]. Protective HA stalk antibody responses
were efficiently induced in mice, rabbits, and ferrets that were immunized with an mRNALNP encoding for a full-length H1 HA [410]. Since HA stalk antibodies are not efficiently
induced by seasonal vaccine platforms, which include full-length HA, this would suggest
the mRNA-LNP platform is capable of directing the immune response towards canonically
subdominant epitopes, even in the presence of the immunodominant HA head. The
mRNA-LNP platform has also been shown to induce robust, protective antibody responses
in the presence of high levels of antigen-specific maternal antibodies in infant mice [411].
These results suggest the mRNA-LNP platform may be able to overcome the hurdle of
decreased antigen availability for a de novo antibody response, or epitope masking, by
pre-existing antibodies directed against the HA stalk domain. Additional studies are
required to determine if the mRNA-LNP platform can efficiently induce a de novo response
in an immunologically experienced individual against heterologous strains in the face of
preferential memory B cell recall.
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Section 4.5 - Criteria for a universal influenza vaccine
The NIAID recently released a strategic plan for the development of a universal
influenza vaccine [412]. The strategic plan identifies the criteria that would define a
universal influenza vaccine. In this final section I will use these criteria to synthesize how
the work presented here fits into the bigger picture in the pursuit towards an HA stalkbased universal influenza vaccine.
Criteria 1: A universal influenza vaccine must be at least 75% effective.
As discussed in Chapter 2, the protective effect size of HA stalk antibodies is small
[344], conferring about a 14.2% reduction in risk of infection for every 2-fold increase in
HA stalk titer (Table 2.2). Investigations into the protective threshold and induction of stalk
antibodies will help determine if HA stalk antibodies can reach this level of efficacy.
Additionally, it is important to note that the data presented in Chapter 2 was generated
using serum samples collected through the Hospitalized Adult Influenza Effectiveness
Network (HAIVEN), which was created to estimate how effective the seasonal influenza
vaccine is in preventing severe influenza disease [413]. Most vaccine effectiveness
networks are focused on primary care cohorts to assess for protection against infection,
rather than protection against severe disease. It is possible that the protection mediated
by HA stalk antibodies will not be as effective at protecting against infection in a primary
care setting. This would be a stumbling block for vaccine approval, as any new vaccine
would have to demonstrate equivalent or improved effectiveness compared to the current
seasonal vaccine [414].
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Criteria 2: A universal influenza vaccine must be able to protect against both group
1 and group 2 influenza A viruses.
In Chapter 1 I described the epitopes of the stalk domain that are conserved to
varying degrees between influenza A viruses (Figure 1.3). Epitope 1, the conformationallydependent epitope that spans the HA1-HA2 interface, is where many of the wellcharacterized broadly, neutralizing mAbs bind (Figure 1.3). This epitope is conserved
across all influenza A viruses, and several human monoclonal antibodies have been
identified that can neutralize group 1 and group 2 influenza A viruses by binding to this
epitope [147, 148, 227, 283]. In Chapter 2, we demonstrated that the general population
has quantifiable levels of serum antibodies that compete for binding to epitope 1 (Figure
2.2), which suggests that a vaccine aiming to boost memory B cell responses in the
population that can target this cross-group neutralizing epitope may be a feasible strategy.
Investigations into the pre- and post-vaccination prevalence of memory B cells that target
this epitope will be very useful in determining if broadly neutralizing responses can indeed
be elicited by HA stalk-based vaccine candidates. Additionally, these types of studies
would determine if targeting this highly conserved cross-group epitope is a way to
circumvent the difficulty of immune imprinting.
Criteria 3: A universal influenza vaccine must have durable protection for at least
one year.
In Chapter 3 we presented in vitro evidence indicating the H1 HA stalk domain has
not experienced antigenic drift over the past decade, indicating this domain is a durable
vaccine target (Figure 3.2, 3.3, and 3.4). However, if an HA stalk-based vaccine is
deployed, immune pressure will be increased on the HA stalk domain. Therefore, it is
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important to assess the consequences of boosted HA stalk antibody responses on the
ability of the HA stalk domain to experience antigenic drift.
While vaccine platforms have been designed to specifically boost the HA stalk
antibody response, this domain is still immunosubdominant to the HA head in the context
of a natural infection. Some evidence suggests that HA head-focused responses can
overwhelm boosted HA stalk memory responses upon re-exposure to similar strains [156].
Therefore, it is important to determine if the prevalence of HA stalk-specific plasma cells
and memory B cells is maintained in the context of natural infection with influenza strains
similar to strains previously encountered by that individual.
Additionally, while the protective potential of Group 2 HA stalk antibodies were not
addressed in this work, it is important to note that the HA stalk domain of Group 2 HA’s
seem to have a higher propensity for antigenic drift compared to Group 1 HAs [415]. This
indicates the HA stalk domain of Group 2 influenza viruses may not be a durable target
for a universal influenza vaccine, and should be carefully assessed for antigenic drift while
under increased immune pressure.
Criteria 4: A universal influenza vaccine must be suitable for all ages.
Immune imprinting is likely the biggest hurdle for the successful development of a
truly universal influenza vaccine, regardless of the viral target. We demonstrated that H1
HA stalk antibody titers were associated with protection in a cohort of individuals, greater
than 60% of whom were over age 50 and would have likely encountered a Group 1
influenza virus as their primary exposure (Figure 2.1 and Table 2.1). However, due to the
immune bias introduced through the primary influenza exposure, it may be difficult to
induce protective levels of HA stalk antibodies against the Group 2 HA stalk domain.

109

Future work will be required to determine if an HA stalk-based vaccine can overcome this
imprinting effect, whether through higher doses, adjuvants, or novel vaccine platforms.

Section 4.6 - Concluding remarks
The pursuit of an HA stalk-based universal influenza vaccine is in full-swing, with
human clinical trials already underway for two different HA stalk-based platforms. Our
work has shown that HA stalk antibodies are associated with protection against influenza
infection and severe disease, and have demonstrated the durability of the H1 HA stalk
domain as a target for a universal influenza vaccine. However, there are still many
unanswered questions regarding the induction and cross-group neutralizing potency of
HA stalk antibodies. It is of the utmost importance to determine the protective threshold of
HA stalk antibodies to use as an absolute correlate of protection and to develop assays
that can accurately measure all the protective mechanisms employed by these antibodies.
These tools and surrogate markers will be the cornerstone for determining
seroconversion, vaccine efficacy, and immunological endpoints for vaccine trials.
Finally, I have illustrated how the work presented in this thesis can be integrated
into future studies addressing the NIAID’s strategic plan for the rational design of a
universal influenza vaccine. Although the development of a universal influenza vaccine
will likely be an iterative process, the lessons learned will enhance our understanding of
the human immune response towards evolutionarily conserved viral targets and how to
tailor this response through vaccine design to capitalize on the unique functions of these
protective antibody subsets.
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